

Leo J. Fitzpatrick LT, USPHS

APPROVED:	
Chair: Maura S. McAuliffe, CRNA, Ph.D.	Date
Member: J. Frank Tish, CRNA, Lt Col., USAF	Date
Member: Eugene Levine, Ph.D.	Date
APPROVED:	
Faye G. Abdellah, Ed.D., Sc.D., RN, FAAN Dean	Date

Report Documentation Page

Form Approved OMB No. 0704-018

Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.

1. REPORT DATE OCT 2000	2. REPORT TYPE N/A	3. DATES COVERED
4. TITLE AND SUBTITLE	5a. CONTRACT NUMBER	
THE CORRELATION BETWEEN END-TIDAL CARBON DIOXIDE MEASURED BY CAPNOXYGENTM MASK AND NASAL CANNULA		5b. GRANT NUMBER
		5c. PROGRAM ELEMENT NUMBER
6. AUTHOR(S)		5d. PROJECT NUMBER
Leo James Fitzpatrick, BA, BSN		5e. TASK NUMBER
		5f. WORK UNIT NUMBER
7. PERFORMING ORGANIZATION NAM Uniformed Services University		8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)		10. SPONSOR/MONITOR'S ACRONYM(S)
		11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION/AVAILABILITY STATEMENT

Approved for public release, distribution unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT

The use of capnography during general anesthesia has become a standard of care for all anesthesia providers and is considered an essential monitoring devise. The relationship of end-tidal carbon dioxide (ETCO2) to arterial carbon dioxide in intubated patients has been well established by Saunders, and colleagues (1994). Attention has focused on capnography in sedated, nonintubated patients where ETCO2 was not monitored and patients had associated comorbidities. Studies also have documented a correlation between the accuracy of ETCO2 to arterial carbon dioxide during spontaneous ventilation using a carbon dioxide (CO2) sampling device through a prong in an oxygen (O2) nasal cannula. In this study, a single-use medium concentration O2 face mask designed to deliver oxygen while monitoring ETCO2 in spontaneously breathing patients was used. The accuracy of the measured ETCO2 was compared to a standard nasal cannula sampling port in 13 normal healthy volunteers. There was a positive correlation between the ETCO2 of both devices with and without the addition of oxygen. Mean ETCO2 measurements with the mask decreased in proportion to increasing oxygen flows, while mean ETCO2 with the nasal cannula remained consistent. Sixty one percent of volunteers stated the mask was more comfortable to wear during their testing experience, and half stated they would prefer to wear the mask over the cannula for a procedure lasting more than one hour.

15. SUBJECT TERMS

capnography, end-tidal carbon dioxide, nasal cannula

16. SECURITY CLASSIFIC	CATION OF:		17. LIMITATION OF	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified	SAR	69	RESI ONSIBLE I ERSON

DISCLAIMER STATEMENT

Department of Defense

This work was supported by the Uniformed Services University of the Health Sciences Protocol No. T061BD-01. The opinions or assertions contained herein are the private opinions of the author and are not to be construed as official or reflecting the views of the Department of Defense or the Uniformed Services University of the Health Sciences.

COPYRIGHT STATEMENT

The author hereby certifies that the use of any copyrighted material in the thesis entitled:

THE CORRELATION BETWEEN END-TIDAL CARBON DIOXIDE MEASURED BY CAPNOXYGEN $^{\rm TM}$ MASK AND NASAL CANNULA

beyond brief excerpts is with the permission of the copyright owner, and will save and hold harmless the Uniformed Services University of the Health Sciences from any damage which may arise from such copyright violations.

ABSTRACT

The use of **capnography** during general anesthesia has become a standard of care for all anesthesia providers and is considered an essential monitoring devise. The relationship of end-tidal carbon dioxide (ETCO₂) to arterial carbon dioxide in intubated patients has been well established by Saunders, and colleagues (1994). Attention has focused on capnography in sedated, nonintubated patients where ETCO₂ was not monitored and patients had associated comorbidities. Studies also have documented a correlation between the accuracy of ETCO₂ to arterial carbon dioxide during spontaneous ventilation using a carbon dioxide (CO_2) sampling device through a prong in an oxygen (O_2) nasal cannula. In this study, a single-use medium concentration O₂ face mask designed to deliver oxygen while monitoring ETCO₂ in spontaneously breathing patients was used. The accuracy of the measured ETCO₂ was compared to a standard **nasal cannula** sampling port in 13 normal healthy volunteers. There was a positive correlation between the ETCO₂ of both devices with and without the addition of oxygen. Mean ETCO₂ measurements with the mask decreased in proportion to increasing oxygen flows, while mean ETCO₂ with the nasal cannula remained consistent. Sixty one percent of volunteers stated the mask was more comfortable to wear during their testing experience, and half stated they would prefer to wear the mask over the cannula for a procedure lasting more than one hour.

Key Words: capnography, end-tidal carbon dioxide, nasal cannula

by

Leo James Fitzpatrick, BA, BSN

THESIS

Presented to the Graduate School of Nursing Faculty of the Uniformed Services University of the Health Sciences in Partial Fulfillment of the

Requirements for the

Degree of

MASTER OF SCIENCE
UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES
October, 2000

FOREWORD

This research was conducted to provide information to all anesthesia providers who have strived to provide the best care possible to their patients during monitored anesthesia care procedures or conscious sedation.

DEDICATION

I would like to dedicate this research to my two children, Kelly and Danny, who endured the long hours and the separation that was necessary to complete this project. Their strength and support allowed me to be successful. I would also like to that my committee members, as well as Captain Jane McCarthy, who helped in the genesis of this project.

TABLE OF CONTENTS

PREFACEi
DEDICATIONii
ACKNOWLEDGEMENTii
LIST OF TABLESiv
LIST OF FIGURESv
CHAPTER I. INTRODUCTION
Background of the Problem1
Statement of the Problem
Aim of the Study4
Research Questions5
Research Variables5
Research Hypothesis
Conceptual Model and Theoretical Framework5
Definitions7
Assumptions8
Limitations of the Study8
CHAPTER II. REVIEW OF THE LITERATURE10
Introduction
Review of the Literature10
Summary17

CHAPTER III. METHODOLOGY	19
Introduction	19
Research Design and Procedures	19
Sample	21
Measurement	21
Data Analysis	22
Summary	23
CHAPTER IV. DATA ANALYSIS	24
Introduction	24
Characteristics of Study Sample	24
Data Analysis	24
CHAPTER V. SUMMARY, CONCLUSIONS AND RECOMMEND	DATIONS30
Introduction	30
Conclusions	30
Recommendations for Future Study	32
Summary	33
REFERENCES	35
APPENDICES	39
APPENDIX A. Health Survey Questionnaire	
APPENDIX B. Informed Consent Form	
APPENDIX C. Post-testing Questionnaire	
APPENDIX D. Data Analysis Tables by Subject	

LIST OF TABLES

Table 1. Nasal Cannula Mean ETCO ₂ Measurement by Oxygen Flow	25
Table 2. CAPNOXYGEN TM Mask Mean ETCO ₂ Measurement by Oxygen Flow	26
Table 3. Differences in Mean ETCO ₂ for Mask and Nasal Cannula by Oxygen Flow	27
Table 4. ETCO2 Correlation of Coefficent for Mask and Nasal Cannula By Oxygen Flow	28

LIST OF FIGURES

Figure 1. Mean ETCO2 by Device,	
% Variance	27

CHAPTER I: INTRODUCTION

Background of the Problem

End-tidal carbon dioxide (ETCO₂) measurement by a capnograph is a valuable monitor of patient ventilation during anesthesia. It is a gold standard of care recognized by the American Association of Nurse Anesthetists (1992) and the American Association of Anesthesiologists for all patients receiving general endotracheal anesthesia. Benumof (1998) states capnography should be considered an essential monitor always used by anesthesia providers.

Capnography is a method of measuring carbon dioxide (CO₂) in expired gas by the presence of a digital readout and plots airway CO₂ concentrations as a function of time. Before the 1960s many anesthesia providers assessed ventilatory adequacy by the presence of cyanosis (Wren, 1994). In 1966 findings on the reliability of capnography and its many applications in clinical practice were presented at a meeting of the Association of Anaesthetists of Great Britain and Ireland. Takki and associates (1972) demonstrated the reliability and validity of capnography in the estimating ETCO₂ during general anesthesia with intubated patients which was substantiated by other studies through the 1980s and early 1990s.

To improve patient safety and decrease anesthesia morbidity and mortality, attention focused on the use of capnogram monitoring in awake, nonintubated patients following Caplan and associates study describing 14 cases of sudden cardiac arrest in otherwise healthy patients who received spinal anesthesia (Caplan, Ward, Posner, & Cheney, 1988). The increase in outpatient surgery with frequent conscious sedation anesthesia during this time also sparked interest in methods to accurately measure ETCO₂

in nonintubated sedated patients.

Over the past decade studies demonstrated a range of accuracy of ETCO₂ compared to arterial carbon dioxide (PaCO₂) measurements obtained during spontaneous ventilation using a CO₂ sampling device attached to catheters positioned either in the nasal cavity or in the nasopharynx. Campbell, McLeod, Bissonnette, and Swartz (1994) found a high degree of reliability between ETCO₂ and PaCO₂ readings via a 5 cm 16 gauge catheter taped below the nares of 60 pediatric patients. Oberg, Waldau and Larsen (1995) found accurate and consistent ETCO₂ measurements could be obtained by a CO₂ sampling port inserted in a thin catheter in different locations between the hypopharynx and nasopharynx when compared to a nasal cannula sampling port. Conversely, Ivens, Verborgh, Phan Thi and Camu (1995) reported ETCO2 measurements during spontaneous ventilation with a nasal sampling device is affected by inadequate sampling of alveolar air, mixing of inspired and expired gases, and the occurrence of ambient air leaks in nonintubated patients. The authors said these variables made the use of an ETCO₂ nasal sampling device with an oxygen facemask a doubtful indicator of arterial CO₂ concentrations when compared to using a laryngeal mask airway. Three other studies found measurement mechanics can also affect the accuracy of ETCO₂ readings with a nasal sampling device (Brunner & Westenskow, 1988, From & Scamman, 1988, Fukuda, Ichinohe, & Kaneko, 1997). High ventilatory frequency, capnography transport delay, and supplemental oxygen, as well as patient variables such as nasal obstruction, a perforated septum, hypoventilation, and mouth breathing all lower ETCO2 measurements. These variables have made the use of the nasal sampling port problematic in awake, nonintubated patients especially children and patients with high respiratory

rates or mouth breathing.

There have been many anecdotal reports describing attempts made to control these variables. Some clinicians moved the nasal sampling port from nose to mouth when the patient converted to mouth breathing. Others have modified an existing oxygen mask by cutting it or attaching the capnograph probe to various locations inside the mask surface (Asai, 1994; Bromage, 1996; Inomata & Nishikawa, 1992; Langer, 1996; Bromage, 1996). While some investigators reported accurate ETCO₂ measurements following these modifications, others report problems with catheters occluding, kinking and falling out of the mask.

The correlation of ETCO₂ to arterial carbon dioxide (PaCO₂), which is considered the gold standard indicator of alveolar ventilation has been well described in endotracheally intubated patients undergoing mechanical ventilation (Saunders et al., 1994). Studies on the correlation of ETCO₂ to PaCO₂ measured by nasal or nasopharyngeal catheter devices in spontaneously breathing, nonintubated patients have documented wide variations in reliability. These variations may be due to patient to patient variability in oxygen administration, mouth breathing, ambient air leaks and catheter occlusion or displacement. The correlation of ETCO₂ to PaCO₂ with simultaneous oxygen administration in spontaneously breathing patients using a facemask specifically designed for both capnography and oxygen delivery functions has not been described. Nor is it known how well this device measures ETCO₂ compared to a nasal sampling catheter.

Statement of the Problem

In 1998 CAPNOXYGENTM LLC (Lebanon,TN) produced a unique clear resin single use facemask. The design of this facemask is specifically for delivering supplemental oxygen and monitoring ETCO₂ in spontaneously breathing nonintubated adult patients.

Design features include a bevel tip sample tube in the mid dome of the face mask which connects to any sidestream CO₂ sample system to via a female Luer connector on the CAPNOXYGENTM mask. The mask is contoured to prevent ambient air leaks while delivering up to 6 liters/minute (L/min) of supplemental oxygen (O₂). A literature search on MEDLINE and CINNAHL (1990-2000) found no studies that evaluate ETCO₂ measurements with human subjects using the CAPNOXYGENTM mask.



Figure 1. The CAPNOXYGEN TM mask

Source: With permission, CAPNOXYGENTM LLC, (1998)-company product brochure.

Aim of the Study

The aim of this study was to measure ETCO₂ measurements obtained by the CAPNOXYGENTM (1998) mask. The measurements were correlated to ETCO₂ measurements obtained from a CO₂ nasal sampling port commonly used in operating rooms which has been found to be accurate (Campbell et al, 1994). ETCO₂ readings from the CAPNOXYGENTM mask will be correlated to those of the nasal cannula sampling port.

Research Questions

This study tested for the statistical significance of the coefficient of correlation between the two methods of measuring ETCO₂ by answering the following questions:

- 1. Is there a statistically significant difference in ETCO₂ measurements without supplemental O₂ between the CAPNOXYGENTM (1998) mask compared to ETCO₂ obtained by a standard CO₂ sampling port inserted into one prong of a nasal cannula?
- 2. Is there a statistically significant difference between diluted (with O_2 flow) ETCO₂ measurements between the CAPNOXYGENTM (1998) mask and nasal cannula catheter?

Research Variables

The dependent variable identified in this study was ETCO₂ as measured by CAPNOXYGENTM mask and nasal cannula with and without oxygen administration.

The independent variables identified in this study were the use of (a) the mask and (b) nasal cannula with a sampling port inserted into one prong to obtain ETCO₂ measurements.

Conceptual Model and Theoretical Framework

The Betty Neuman Systems Model (Murray, 1998) is based on theories of stress adaptation. In the Neuman model, the person is viewed as a multidimensional whole, in constant dynamic interaction with the environment. Neuman defines a stressor as any environmental force that can potentially affect the stability of the system. Stressors may be intrapersonal, interpersonal, or extrapersonal. The Neuman's Systems Model was chosen as a conceptual framework for this study because of its orientation with systems theory, a method involving processes and outcomes that is well suited to anesthesia and the process of assessing and testing new equipment.

Three key concepts in Newman's theory are stress, homeostasis, and patient perceptions (Martin, 1996). The nurse's role in this model is to address variables affecting the patients' response to stressors and reduce risk factors associated with them. The role of the nurse anesthetist within Neuman's framework is to support the normal line of defense of the client by impeding the stressors the client experiences. Within the framework of this study, these intrapersonal stressors could be defined as hypoxia, hypoxemia, and hypercarbia. Extrapersonal stressors could be defined as the nurse anesthetist's ability or inability to detect those threats during anesthesia care by obtaining accurate capnogram and capnography measurements. Homeostasis is a concept that is well integrated in anesthesia practice as evidenced by the constant vigilance required of the nurse anesthetist during the delivery of anesthesia care.

Neuman believes nurses receive training in the natural and behavioral sciences and are expected to conceptualize it in their own way (Martin, 1996). This point is very pertinent to the development of the product to be assessed in this study. According to

company spokesman, R. A. Davenport (personal communication, November 15, 1998), the CAPNOXYGENTM (1998) mask was developed by a certified nurse anesthetist (CRNA) as a method to monitor capnography while providing oxygen to spontaneously breathing nonintubated patients.

Definitions

The following are key words that were used in this study related to capnography:

<u>Conceptual Definition of Capnography</u>

Capnography was defined as the nurse anesthetists interventions to monitor homeostasis and eliminate the stressors as previously noted.

Operational Definitions

<u>Capnogram.</u> A graphic record of inspired and expired carbon dioxide concentrations in the form of continuous waves (Miller, 1992).

<u>Capnograph.</u> A monitor which produces a record of instantaneous CO₂ concentrations of inspired and expired gases by the absorption of infrared light by CO₂ as recorded on a capnogram (Miller, 1992).

Sidestream capnograph. This is also known as an aspiration capnograph, which continuously suctions gas from the breathing circuit into a sample cell within the capnometer monitor. CO₂ concentration is determined by comparing infrared light in a sample cell with a chamber free of CO₂ (Morgan & Mikhail, 1996).

Ohmeda Rascal II sidestram capnograph. The specific capnograph that was used to obtain ETCO2 measurements for this study. According to R. Kyle (personal communication, January 26, 2000), manager of the anesthesia simulator laboratory at USUHS, this model is calibrated by a company technician every six months according to

Ohmeda Corporation's specifications for validity and reliability. This model was recalibrated in April 2000 before testing began.

<u>Capnometry</u>. A device for measuring for measuring the end-tidal partial pressure of carbon dioxide (ETCO₂) (Miller, 1992).

End-Tidal Carbon Dioxide Tension (ETCO₂). The partial pressure of CO₂ in end tidal exhaled gas, which is primarily alveolar gas (PACO₂). ETCO₂ is used clinically as an estimate of PaCO₂ (Morgan & Mikhail, 1996).

Assumptions

- 1. The capnometer and capnograph was calibrated accurately and the gas samples were obtained correctly as observed by an appropriate ETCO₂ waveform.
- 2. The CAPNOXYGENTM mask and nasal cannula remained patent to accurately measure ETCO₂.
- 3. Volunteers who identified themselves as normal healthy subjects without any evidence of preexisting pulmonary or cardiac pathology or abnormalities were healthy and remained so during the study.
- 4. Volunteers rate and depth of respirations remained relatively consistent during data collection to provide accurate ETCO₂ measurements with both devices.

Limitations of the study

1. In this study the CAPNOXYGENTM mask was tested within the anesthesia simulator department of a university medical center with normal healthy volunteers. A larger study that includes testing in a clinical setting at multiple facilities would increase the generalizability of the results.

- 2. Subjects were experienced nurses who know that a nasal cannula delivers oxygen best if they nose breathe.
- 3. ETCO₂ was measured by nasal cannula as the dependent variable without correlating it to PaCO₂. While desirable, the actual measurement of PaCO₂ obtained via an arterial blood gas sample is invasive and potentially expensive. Moreover, the study sought to use normal healthy volunteers to eliminate extraneous variables caused by preexisting pulmonary and cardiovascular pathology, as well as the respiratory depressant effects of volatile anesthetics and narcotics. The intent of this investigation was to compare the capnography and oxygen administration functions of this new product to the method currently used in most anesthesia clinical settings.

CHAPTER II: REVIEW OF THE LITERATURE

Introduction

The purpose of this review is to identify relevant recent research about the measurement of ETCO₂ in spontaneously breathing patients. This review will provide insight into the problem of obtaining consistent ETCO₂ measurements with a nasal cannula, pharyngeal catheter, modified oxygen mask, or a nasal/oral discriminate sampling system, and lay the groundwork for investigating the correlation of ETCO₂ measurement by capnography oxygen mask and a CO₂ nasal sampling port.

Review of the literature

Oberg et al.(1995) investigated the influence of nasal oxygen administration, position of a CO₂ sampling catheter, and mouth breathing on ETCO₂ measurements obtained from a pharyngeal catheter. In a study of nine healthy normal volunteers, they found reliable capnograph tracings were obtained from a thin catheter placed in different positions in an unintubated airway. Subjects received oxygen at a rate of two to 6.1 liters per minute (l/m) via nasal cannula without interference with the accuracy of the ETCO₂ measurements from the pharynx. Oberg and colleagues found the position of the catheter in either the hypopharynx, oropharynx, or nasopharynx had little effect on the ETCO₂, and concluded that the catheter could be placed where it causes the subject the least discomfort. The authors also found that mouth breathing caused a mean decrease in ETCO₂ of only 2.5 mmHg compared to nose breathing.

The study by Oberg et al.(1995) provided evidence of ETCO₂ reliability regardless of airway position or mouth breathing, its small sample size and use of a potentially irritating pharyngeal catheter in a nonintubated airway limited its usefulness. Further,

Bromage (1996) following Oberg and associates (1995) method, reported frequent patient discomfort and mucous obstruction when placing the CO₂ port deeper than 2 cm inside the external nares without any compensatory increase in the level of ETCO₂.

Campbell et al. (1994) examined the reliability of ETCO₂ as an estimate of PaCO₂ in spontaneously breathing infants and children. The ETCO₂ of 40 patients in a post anesthesia care unit (PACU) was obtained by a 5 cm 16 gauge catheter taped below the external nares, and this measurement was compared with the PaCO₂ drawn from an indwelling arterial line. Patients were equally divided into a group of 20 infants less than 12 kg and a group of 20 children greater than 12 kg. In addition, the investigators examined 20 additional patients during inhalation anesthesia. The ETCO₂ was measured from two locations: the proximal end of an elbow connector of a T-piece breathing system with a gas-sampling port in the elbow connector; and from a 5 cm 16 gauge cannula inserted through the sampling port. Campbell and associates found a correlation of .80 between ETCO₂ and PaCO₂ in PACU patients regardless of weight. The average PaCO₂ — ETCO range was —0.6 3.6 mmHg. Patients studied during mask anesthesia showed a stronger correlation between ETCO₂ and PaCO₂ when ETCO₂ was sampled from the cannula. The average PaCO₂ - ETCO₂ range was 3.5 ± 4.8 mmHg (cannula) and $8.6^{\pm}4.5$ mmHg (elbow) (P < 0.05). The results suggested ETCO₂ monitoring was a reliable method for assessing adequacy of ventilation in spontaneously breathing children. These results were significant in a patient population that has a rapid respiratory rate who are obligate nose breathers with frequent nasal congestion, factors which could have reduced the correlation of ETCO₂ to PaCO₂. These findings

corroborated earlier studies of spontaneously breathing adults measured with a sampling port inside a nasal cannula.

Wright (1992) described the use of nasal capnography in monitoring heavily sedated emergency department adult patients. The prospective, noncontrolled clinical observational study monitored twenty-seven patients requiring sedation with benzodiazepines and/or narcotics for painful procedures. Ventilatory status was monitored by capnography by nasal cannula as well as pulse oximeter before, during, and after the administration of the sedative agents. The results were that the mean ETCO₂ increased 6.2% and SaO₂ decreased 3.7% during the procedures. One patient developed clinically significant apnea detected by apnea alarms on the capnometer and oximeter, and eight others developed clinically silent hypoxemia (SaO₂ less than 90% with no other physical or vital sign changes indicating cyanosis) with simultaneous increase in nasal ETCO₂. Wright concluded the use of pulse oximetry and capnography by nasal cannula is recommended for the detection of unrecognized hypoxemia during conscious sedation. He added that more research and clinical experience is required before routine use of capnography was recommended in the emergency department setting, as cannula occlusion is an occasional problem. This study emphasized the clinical significance of capnography as measured by a nasal cannula.

Saunders et al. (1994) investigated the accuracy of ETCO₂ compared to PaCO₂ in sleeping patients undergoing evaluation for sleep-disordered breathing and nocturnal ventilatory insufficiency. Capnograph readings were obtained for three groups of patients by a capnometer probe suspended in a loose-fitting aerosol facemask with extra holes cut out to minimize dead space. ETCO₂ measurements were made with

simultaneous arterial blood gas samples in 19 patients spontaneously breathing room air, (condition one), in 13 patients receiving supplemental oxygen via nasal cannula (condition two), and in 22 patients receiving nocturnal positive pressure ventilatory assistance (condition three). Saunders and colleagues found significant scatter in the PaCO₂ vs. ETCO₂ relationship. Only 23 % of the variability in PaCO₂ was explained by the variation of ETCO₂ in condition one, and only 15 and 20 % of the variability in PaCO₂ was explained by the variation of ETCO₂ during conditions two and three, respectively. Over 21% of patients had average ETCO₂ value in error by more than 10mmHg compared to PaCO₂ during condition one, 46.2% in condition two, and 63.7% in condition three. The authors concluded ETCO₂ measured with a facemask is not a consistently accurate reflection of PaCO₂ during sleep studies.

While Sanders et al. (1994) found a statistically significant variation in the PaCO₂-ETCO₂ relationship, the study failed to use a consistent method of oxygen administration and placement of the CO₂ sampling catheter between the three study groups. For example, patients in condition 2 had supplemental oxygen by nasal cannula with the CO₂ sensor hung suspended above in a loose fitting mask, while patient in condition 3 had positive pressure ventilation by a full facemask interface or by nasal cannula. The use of positive versus passive oxygen pressure and placement of the CO₂ catheter within a loose fitting mask with ambient air leaks may have increased the PaCO₂-ETCO₂ differences.

Another study by Ivens, et al. (1995) examined the relationship between PaCO₂ and ETCO₂ during inhalation anesthesia using a laryngeal mask airway (LMA) compared to facemask. Eighteen patients undergoing plastic surgery on an arm or leg were divided into two groups: nine patients had their airway maintained by a LMA, and nine received

an oral airway and facemask. Following induction, the airways of both groups were checked for leaks by auscultation and by manually increasing airway pressure up to 15 cm H_2O . Arterial blood gas samples were drawn at four different intervals during each procedure, while mean $ETCO_2$ measurements from the capnograph were averaged from all breaths occurring during a period of 20 seconds before the arterial blood sample. $ETCO_2$ sampling occurred at the standard proximal connector in the LMA group and between the mask and elbow piece in the facemask group. The authors found both $ETCO_2$ and $PaCO_2$ were higher in the LMA group: $Pa-ETCO_2$ differences ranged from 0.13 to 4.13 kPa in the facemask group, and from 0.0 to 1.73 kPa in the LMA group. Using pooled data regression analysis, Ivens and colleagues also found a better correlation coefficient was found in the LMA group (r = 0.91, p < 0.001) than in the facemask group (r = 0.62, p < 0.01). The authors concluded estimation of $PaCO_2$ by monitoring $ETCO_2$ is more reliable with a LMA than a facemask.

While the results of the Ivens et al. (1995) study were both clinically and statistically significant in a practice setting where an LMA is a viable option. During conscious sedation procedures, it may be impractical and unnecessary to use a LMA compared to nasal cannula or facemask.

Other studies have identified mechanical and physiologic variables in the measurement of ETCO₂ in sedated, spontaneously breathing patients that have been demonstrated to be unreliable when compared to the actual measurement of ETCO₂ in intubated patients. From and Scamman (1988) suggested respiratory rates greater than 30 breathes per minute lowers ETCO₂ due to gas mixing of adjacent tidal volumes within a nasal sampling catheter. Brunner and Westenskow (1988) state the effect of capnography

transport delay — the time needed to aspirate end-tidal gases through the sampling catheter — may also underestimate ETCO values during rapid respiratory rates due to diluted gas in the sample catheter. Fukuda, et al. (1997) found the influence of both biological and mechanical factors can decrease the reliability of ETCO₂ measurements. Fukuda and colleagues suggest tidal volumes greater than 500 ml and respiratory rates less than 20 per minute, along with small diameter nasal prongs, shorter nasal cannula length, and smaller diameter nasal cannulas results in improved reliability of ETCO₂ measurements due to less dead space and turbulence within the cannula. Two other studies suggested that anatomic and physiologic changes in patients, including nasal obstruction, perforated septum, hypoventilation, large arterial to end-tidal carbon dioxide gradients, and mouth breathing, all lower ETCO₂ values, depending on the measurement method and site (Bhavani-Shankar, Moseley, Kumar, & Delph, 1988, Szaflarski & Cohen, 1991). In addition, obstruction of catheters, inconsistent measurement sites and dilution of CO₂ by supplemental oxygen are commonly cited problems that cause reduction in measurement accuracy.

Later studies described adaptations and modifications in equipment that occurred as anesthesia providers attempted to overcome the extraneous variables identified above as adversely affecting the correlation of ETCO₂ and PaCO₂. Anecdotal reports in the literature by Asai (1994), and Risdall and Geraghty (1994) found improved capnography tracings during regional anesthesia by connecting the CO₂ sensor through a vent hole in the body of a Hudson oxygen mask by removing the distal Luer connector and then reattaching it to the inside of the mask surface. Inomata & Nisikawa (1992) found success in attaching the CO₂ probe by a separate elastic strap under the patient s nostrils

inside a normal oxygen mask. They noted a leak around the facemask may have diluted expiratory CO₂, but the method was successful in detecting a 25 second period of apnea in a 71 year old man undergoing a hernia repair. Langer (1996) hypothesized that parturients often removed an oxygen mask modified for capnography during labor because it was too difficult to breathe. He reported acceptable capnography tracings and a 3-8 % increase in oxygen saturation by cutting a mask just above the vent holes to allow the quick elimination of CO₂, and applying the CO₂ sensor catheter loosely in the mask between the nose and upper lip. Langer failed to address the possible movement of the catheter inside the mask during active labor, and did not define acceptable capnograph tracings.

Only one study has attempted to limit the influence of mouth breathing by providing a new ETCO₂ measurement device capable of selectively sampling from either nasal and/or oral routes. Derrick, Waters, Kang, Cwalina and Simmons (1993) investigated the correlation of a nasal/oral discriminate sampling system (NODSS) to PaCO₂. The NODSS looks similar to a classic nasal cannula. Nasal prongs can be telescopically extended to maintain their position, and a multiperforated adjustable oral sampling cylinder is suspended between the upper and lower lip. Independent nasal and oral sampling lines are connected to a three-way stopcock to enable the operator to selectively sample each site independently or both sites simultaneously while delivering oxygen through one of the nasal prongs. Derrick and colleagues tested the device on twenty-four PACU patients divided into two groups based on health status and found a Pearson s product — moment correlation coefficient (r value) of 0.60 to 0.84 between PaCO₂ values for nasal and/or oral ETCO₂ measurements. They also suggested there

was no significant difference between the mean Pa-ETCO₂ gradient compared to the mean gradient derived by the oral sampling port with this device (P > 0.05). The authors concluded the NODSS was a reliable, effective means of detecting respiratory inadequacy in spontaneously breathing patients.

In reviewing the data from the Derrick et al. (1993) study, it was interesting to note correlations to PaCO₂ were higher with the nasal sampling part of the NODSS with healthy patients, while patients with suspected pulmonary dysfunction more closely correlated with the oral part of the devise. This raises questions concerning the importance of measuring sites in relation to the patient respiratory functioning. Also of concern is the fact that there have been no subsequent studies on the device since the Derrick et al. study. While the company is still marketing the product as the Nazorcap Sampler (NasOrCap Medical, Inc., West Mifflin, PA, 1998) it is unclear if it is commonly used in clinical practice.

Summary

Debate on the correlation of ETCO₂ to PaCO₂ as measured by a nasal cannula, pharyngeal catheter, modified oxygen mask, or nasal/oral discriminate sampling system exists in the anesthesia literature. No one method has sufficiently addressed technical or patient variables which has precluded the reliable estimate of PaCO₂ in spontaneously breathing nonintubated patients compared to intubated patients. While initial results of the NODSS looked promising, its application in clinical practice is unknown and the device has not been followed by further study. Studies by Caplan et al. (1988) and Wright (1992) illustrate the potential morbidity and mortality of patients not monitored for ETCO₂ during regional anesthesia or conscious sedation procedures. A need exists

for the investigation of a device that will address patient and technical variables outlined in this review and provide a consistent and more accurate means to monitor ETCO₂. It should also provide supplemental oxygen to the patient. Recently, a medical equipment manufacturer has designed and manufactured a new, improved mask, which is reported to be a more accurate method to monitor ETCO₂ while simultaneously providing oxygen. In this study I investigated the correlation of ETCO₂ measured by a capnography oxygen mask and nasal cannula.

CHAPTER III: METHODOLOGY

Introduction

In this chapter the methods that were used to determine the correlation between ETCO₂ by nasal cannula and CAPNOXYGENTM mask by using each device on healthy volunteer subjects will be described. The research design, procedures, sample, measurement, and plan for data analysis will be described.

Research Design and Procedures

Following submission and approval of this proposal by the Research Administration Department of the USUHS, data were collected at the anesthesia simulator department at USUHS during the month of April, 2000. The Institutional Review Board (IRB) was contacted as part of this process regarding the protection of human rights for the healthy volunteers for this study. Approval for the study was granted. Both devices have been used safely in clinical practice. Literature from CAPNOXYGENTM LLC (1998) claims there are no contraindications for its use on human subjects, as the mask is made from a medical-grade resin and is latex-free. The safety of nasal cannulas has been well documented in the medical literature.

The CAPNOXYGENTM mask was pilot tested on the anesthesia simulator machine and on two healthy subjects at the Uniformed Services University of the Health Sciences (USUHS) for patency and fit before it was used on human subjects as part of the study. ETCO₂ readings by the mask were correlated to ETCO₂ by nasal cannula with and without oxygen administration to establish a range of values to compare on human subjects. A standard nasal cannula was tested by inserting the lure end to an Ohmeda Rascal II sidestream capnograph. The CO₂ catheter was inserted into one of the prongs

of the nasal cannula by way of a 16-gauge angiocatheter intervenous needleset. The CAPNOXYGENTM mask was similarly connected to the capnograph by attaching the male end of the CO₂ sample line to the female Luer connector on the mask. Oxygen was administered through a standard connection from the Ohmeda anesthesia machine to each device.

Following the completion of a brief health survey (see Appendix A) and informed consent form (see Appendix B), 15 healthy volunteers were asked to lie supine on a examination table in the anesthesia simulator laboratory and randomly select a number to determine whether they will be monitored with the CAPNOXYGENTM mask or nasal cannula first. Subjects were asked to breathe normally for a period of two minutes with either device. The respiratory rate was determined by counting the respirations for 15 seconds and multiplying by four. Subjects were not asked to keep their mouth closed when using the nasal cannula. This might alter the variability inherent in patients who mouth breathe during conscious sedation. After a mean baseline ETCO₂ was established during a two-minute period without oxygen, oxygen was administered at 2, 4, and 6 liters per minute for a period of two minutes. At each level of oxygen administration, an average ETCO₂ reading was taken from either the nasal catheter CO₂ sensor or CAPNOXYGENTM mask CO₂ sensor. Following a two-minute rest period, subjects were asked to breathe normally with the second device for two minutes, and then repeat the same sequence of oxygen administration and average ETCO₂ readings. After the procedure, subjects were asked to complete a brief questionnaire (see Appendix C) regarding the comfort and fit of each device. The entire procedure, including the completion of forms, took no more than 30 minutes for each subject.

Sample

A convenience sample of graduate nursing students at the USUHS was taken following informed consent and satisfactory completion of a verbal health screening questionnaire. Exclusion criteria included a upper respiratory tract infection within 10 days of testing, asthma, smoking, or newly diagnosed pulmonary disease. All subjects had passed semiannual physical exam testing from their respective military services, and had an extensive physical exam screening before being accepted into their graduate education program at USUHS.

The class of 2001 USUHS graduate school of nurse anesthesia students were addressed at a meeting during March, 2000, and explained the purpose, methodology, and risks and benefits of the study and asked for volunteers. All students were given an equal chance to participate. All class members received an informed consent document (see Appendix B) to review at their convenience before consenting to participate in this study.

It was expected that differences in measurements between the two methods would be minimal and variation in differences among subjects would be small. With minimal differences and low variability of the differences, the standard error of the differences expected to be small, therefore, a small sample of approximately 15 subjects was justified.

Measurement

Mean ETCO₂ measurements were recorded during two-minute intervals on a data flow sheet for each method of capnography (see Appendix D). A paired *t*-test was used to determine if there was a significant difference between the ETCO₂ measured by the CAPNOXYGENTM mask and nasal cannula ETCO₂ measurement for each subject.

Statistical significance was accepted at a level of p < 0.05. In addition, correlations were determined between the CAPNOXYGENTM mask and the nasal cannula for each O₂ flow.

Data Analysis

Correlational research is conducted to examine linear relationships between two or more variables and to determine the type (positive or negative) and degree (strength) of the relationship (Burns & Grove, 1997). In this study a Pearson s product-moment correlation coefficient was used to examine the relationship between the two methods of capnography. A positive relationship was defined as one that indicates the variables vary together, where both ETCO₂ measurements either increase or decrease together. The negative or inverse relationship was defined where the two methods of ETCO₂ measurements vary in opposite directions; one variable will increase, the other will decrease. In this study, the strength of the relationship of ETCO₂ between the mask and nasal cannula could range from —1, a perfect negative correlation, to +1, a perfect positive correlation. A score of 0 would indicate there was no relationship between the two devices.

Results recorded on the data sheets were organized by a data dictionary to ease entry of data into a statistical package. The collected data were analyzed using the Statistical Package for the Social Sciences (SPSS), (April, 2000). A Pearson's product-moment correlation coefficient (r) was calculated between the mean ETCO₂ measurements for each O₂ flow for each subject. Using the criteria established by Burns and Grove (1997), an r of 0.1 to 0.3 was considered a weak linear relationship, 0.3 to 0.5 a moderate linear relationship, and above 0.5 a strong linear relationship.

Summary

This study was conducted using a descriptive correlational analysis to compare the ETCO₂ measured by CAPNOXYGENTM mask to the ETCO₂ measured by a nasal cannula. A convenience sample of healthy volunteers was taken over a period less than one month at a university medical teaching facility. Data collection was done to compare the ETCO₂ measurements for each device, the strength of a linear relationship, and the percent of variance.

CHAPTER IV. DATA ANALYSIS

Introduction

In this chapter the results of the study will be presented. Data collection and analysis procedures will be discussed with respect to the aims of the study. Findings will be organized into meaningful groups for interpretation in Chapter Five.

Characteristics of Study Sample

Thirteen subjects were recruited for the study. Eight males and five females ranged in age from 28 — 44 years old. Twelve subjects were active duty military nurses and one subject was an employee of the university s anesthesia department. All subjects completed a health questionnaire and identified themselves as healthy non-smokers without any physical or medical condition that could limit the rate and depth of their respiration. Subjects were also asked to complete a post-test questionnaire in which asked they rated each device according to fit and comfort.

Data Analysis

During the data collection, the fraction of inspired oxygen (FIO₂), oxygen saturation (SaO₂), respiratory rate (RR), and end-tidal carbon dioxide (ETCO₂) of the subjects were recorded every 30 seconds during a two minute interval at each level of oxygen flow (see Appendix D). Extremely small variability between subjects with regard to FIO₂, SaO₂, and RR occurred during the two minute sampling intervals with both the nasal cannula and the CAPNOXYGENTM mask. Therefore, these data will be referred to in the following chapter for trending purposes and will not be discussed here.

In analyzing the mean $ETCO_2$ measurements using the nasal cannula, there was a very small difference noted between the 13 subjects with and without oxygen flow.

Without oxygen flow, the mean ETCO₂ for the nasal cannula was 39.7, with a range of 7.3 (see Table 1). At the highest oxygen flow of 6 liters the ETCO₂ was 40.3, with a range of 12.5.

Table 1.

Nasal Cannula Mean ETCO₂ Measurement by Oxygen Flow.

	O_2 flow	w (l/m)		
0		2	4	6
ETCO ₂ (mmHg) 39	9.7	40.7	41.0	40.3
ard Deviation 2.	.89	3.39	3.60	3.91
num ETCO ₂ (mmHg) 30	6.3	34.3	36.8	34.3
mum ETCO ₂ (mmHg) 43	3.5	46.0	47.3	46.8
e ·	7.3	11.8	10.5	12.5
·	7.3	11.8	10.5	

Mean ETCO₂ measurements with the CAPNOXYGENTM mask were very similar to those of the nasal cannula without oxygen (see Table 2). Mean ETCO₂ was 40.6, with a range of 9.5. However, during oxygen administration, there was a significant and consistent decrease in ETCO₂ with increasing oxygen flow with the CAPNOXYGENTM mask. Mean ETCO₂ at 2 liters was 36.8, at 4 liters was 35.2, and at liters was 33.0. The range of mean ETCO₂ values with the mask during oxygen flow was less than those of the nasal cannula at 6.0, 9.5, and 10.0, respectively.

Table 2.

CAPNOXYGENTM mask mean ETCO₂ measurement by oxygen flow.

O_2 flow (1/m)				
	0	2	4	6
Mean ETCO ₂ (mmHg)	40.6	36.8	35.2	33.0
Standard deviation	2.73	1.78	2.46	2.89
Minimum ETCO ₂ (mmHg)	35.5	32.5	31.5	29.3
Maximum ETCO ₂ (mmHg)	45.0	38.5	41.0	39.3
Range	9.5	6.0	9.5	10.0

In comparing the mean ETCO₂ measurements of each device at each level of oxygen administration, there was a significant increase in the difference of ETCO₂ between the two devices as oxygen flow increased (see Table 3 and Figure 1). Without oxygen, the difference the mask and cannula was only 0.8 torr. However, when oxygen was added, mean ETCO₂ for the mask decreased significantly compared to nasal cannula. Mean ETCO₂ with the mask decreased 9.6% at 2 liters flow and 18.1% at 6 liters flow.


Table 3.

Differences in mean ETCO₂ for mask and cannula by oxygen flow.

		O ₂ flow (la	O ₂ flow (l/m)	
	0	2	4	6
Mask mean ETCO ₂ (mmHg)	40.6	36.8	35.2	33.0
Cannula mean ETCO ₂ (mmHg	g)39.7	40.7	41.0	40.3
Mean difference	0.8	-3.9	-5.8	-7.3
% variance mean difference	2.0	9.6	14.1	18.1
Standard deviation	2.03	3.08	3.44	3.27
Standard error mean	.56	.85	.95	.91

Mean ETCO2 by device, % variance

Figure 1.



In correlating the $ETCO_2$ measurements of each device with and without oxygen, a strong positive linear relationship was found (Table 4). Without oxygen, Pearson s

product-moment correlation coefficient (r) was .74, with a two tailed test of significance (p) of .00. During oxygen administration of 2 and 4 liters per minute, the correlation was not statistically significanct. At two liters of O_2 flow, an r value of .43 (p = .14) was found and 4 liters per minute an r value of .40 (p = .17). However, at 6 liters per minute of oxygen administration, r increased to .57 (p = .04).

Table 4.

ETCO ₂ Correlation of	Coefficient for ma	<u>ısk and nasal c</u>	<u>annula by oxy</u>	<u>gen flow.</u>

O ₂ (1/r	n) <i>r</i>	<u>p</u>
0	.74	.00
2	.43	.14
4	.40	.17
6	.57	.04

In completing the post-testing questionnaire, the 13 subjects were asked Which device was more comfortable to wear during your testing experience and why?. Eight subjects (61%) stated the CAPNOXYGENTM mask was more comfortable. Reasons stated included, There was no pulling on my ears or irritation to my nostrils at high flow rates like the nasal cannula, The cannula dried out my nose, The nasal cannula at six liters of flow hurt my nose, and I don't like things up my nose. Four subjects (31%) responded they preferred the cannula, stating the following reasons: The mask dried out my mouth more, The cannula was less restrictive and easier to draw a breath from; The cannula was just more comfortable to wear. One subject stated he did not prefer

either device, noting The mask was claustrophobic, and the nasal cannula was irritating to my nostrils.

When subjects were asked the question, If this had been a conscious sedation or monitored anesthesia care procedure lasting more than one hour, which device would you prefer to wear?, preferences for the two devices were evenly split. Seven subjects (54%) responded they preferred the mask, while six (46%) preferred the cannula.

When subjects were asked which device provided the best fit for administering oxygen and measuring end-tidal carbon-dioxide, eight (61%) stated the mask, while three (23%) stated the cannula. One subject responded that the cannula provided the best fit for oxygen administration, while the mask provided the best fit for measuring end-tidal carbon dioxide. One subject did not respond to the post-testing questionnaire.

When asked if they described themselves as nose breathers or mouth breathers at rest, all thirteen subjects stated they were nose breathers. However, when asked if they deliberately tried to breathe through their nose while wearing the cannula, five subjects (39%) claimed they did, while eight (61%) stated they did not.

CHAPTER V. SUMMARY, CONCLUSIONS AND RECOMMENDATIONS Introduction

In this chapter, the data will be summarized and conclusions drawn from the study will be presented. Implications for clinical practice will be discussed as well as recommendations for future research.

Conclusions

The aim of the study was to test ETCO₂ measurements obtained by the CAPNOXYGENTM mask and correlate with them to those obtained from of a nasal cannula in 13 healthy normal volunteers. There was a strong, positive correlation between ETCO₂ measured by nasal cannula and CAPNOXYGENTM mask with and without oxygen flow. ETCO₂ correlation was strongest and statistically significant without oxygen flow and at a flow of six liters of oxygen per minute. Correlations decreased slightly during oxygen flows of two and four liters per minute; however they remained in a moderate. linear relationship, as defined earlier in the study. The investigator cannot explain the small decrease in correlations at two and four liters per minute of oxygen between the two devices.

The clinical significance of the mean ETCO₂ measurement differences for each device should be emphasized. The nasal cannula provided a consistent mean ETCO₂ measurement during all levels of oxygen administration. The CAPNOXYGENTM mask showed significant dilution of ETCO₂ as oxygen flows increased. I believe the decrease in ETCO₂ using the mask was due to a dilutional effect of oxygen in the mask. Clinicians using the CAPNOXYGENTM mask should be aware that a decrease in capnometer

readings compared to nasal cannula does not necessarily indicate that their patient is hypoventilating.

The consistency of the mean ETCO₂ readings obtained by the nasal cannula must also be interpreted in the light of the fact 100% of study subjects identified themselves as nose breathers. Furthermore, 39% stated they deliberately tried to breath through their nose wearing the nasal cannula. The majority of these subjects were experienced clinicians who were aware that breathing through their nose would provide more accurate and consistent ETCO₂ readings with the nasal cannula. This may have influenced the effect of the consistent mean ETCO₂ measurements with the nasal cannula across all flows of oxygen.

As previously noted, the differences in the delivered FIO₂ and resulting SaO₂ for each device were small during oxygen administration. Average FIO₂ and SaO₂ at each level of oxygen flow were similar enough not to warrant an analysis for this study. This is not surprising, given all subjects were healthy and were not sedated during the testing. However, the added clinical variables of sedation and coexisting disease could have altered these results. In addition, mechanical differences between the two devices—the nasal cannula prongs have a much smaller diamenter compared to the mask tubing, and one of the prongs of the nasal cannula was partially occluded by the CO₂ sampling tube—could have played a larger role in delivered FIO₂ and SaO₂ when combined with the clinical variables mentioned above.

In discussing the study subjects preferences comparing the fit and comfort of each device, 61% preferred the fit of the mask over the cannula, 54% would prefer to wear the mask over the cannula for a monitored anesthesia case lasting over one hour, and 61%

thought the mask provided the best fit for delivering oxygen and monitoring ETCO₂. In analyzing the subjects responses, it is clear that preferences for the mask or the cannula were based on negative evaluations of the non-preferred device. The fact that there was a close preference for wearing the CAPNOXYGENTM mask during procedures lasting longer than one hour may indicate a prediction of claustrophobia that one subject noted during testing with the mask.

In discussing the feasibility of using a new device in clinical anesthesia practice, cost must be a consideration. A company spokesman noted the retail unit cost of the CAPNOXYGENTM mask is \$3.95. A survey of three military hospitals in a metropolitan area found the average unit cost of a simple nasal cannula was \$2.00, and the cost of a 16 guage intervenous angiocatheter was \$.20. Thus cost differences are not substantial.

Recommendations for Future Study.

Further study should include an effort to replicate this study in the clinical setting with a larger patient sample. A larger, more diverse patient sample would increase the generalizability of the results. In addition, the ability to correlate the ETCO₂ of the CAPNOXYGENTM mask to a arterial blood gas sample (PaCO₂) would provide a more definitive means of determining the accuracy of this device to deliver oxygen and measure end-tidal carbon dioxide. An arterial blood gas would also provide strong evidence to correlate the FIO₂ and SaO₂ delivered by the two devices in this study.

A future study could also examine the correlation of ETCO₂ obtained by mask to other nasal cannula products designed to measure ETCO₂ during monitored anesthesia care procedures. One is the Nazorcap Sampler (NasOrCap Medical, Inc., West Mifflin, PA, 1998), noted in the review of the literature. Another new nasal cannula product

which could be tested is the MAC Safe nasal cannula (Vital Signs, Inc., Totowa, NJ 1999) which is currently in use in clinical practice. These tests could also compare the variables of fit, comfort and cost, which was not the primary aim of this study.

Finally, the ETCO₂ obtained by the CAPNOXYGENTM mask could be compared to other noninvasive methods of measuring end-tidal carbon-dioxide which do not administer oxygen. One such method is the development of the transcutaneous carbon dioxide skin sensor placed on a patient during oxygen administration, which was tested in the Saunders et al. (1994) study.

This study demonstrated a strong association to the Betty Neuman Systems Model of stress and adaptation. A certified registered nurse anesthetist developed the CAPNOXYGENTM mask to address physiologic and mechanical variables which affected the reliability of other methods of providing oxygen and monitoring ETCO₂ in spontaneously breathing patients. Future studies should consider the Neuman Model as a framework for evaluating the CAPNOXYGENTM mask or other methods of oxygen delivery and ETCO₂ monitoring.

Summary

This study showed a positive strong correlation between ETCO₂ measured by nasal cannula and CAPNOXYGENTM mask with and without oxygen flow. Correlation was strongest and statistically significant without oxygen and at six liters per minute of oxygen flow. The nasal cannula provided a consistent mean ETCO₂ measurement during all levels of oxygen administration, while the CAPNOXYGENTM mask showed significant dilution of ETCO₂ as oxygen flows increased. Differences in the delivered FIO₂ and resulting SaO₂ for each device were too small to warrant further analysis.

In considering the feasibility of using a new device in clinical practice, patient preference and cost are important considerations. In this study, a majority of study subjects preferred the fit and comfort of the CAPNOXYGENTM mask over the nasal cannula during their testing experience. A telephone survey of three metropolitan military hospitals revealed the cost of the CAPNOXYGENTM mask is slightly more expensive than the combined cost of a nasal cannula and 16-guage intervenous angiocatheter.

Future studies should consider the use of a larger patient sample which compares the ETCO₂ of the CAPNOXYGENTM mask to PaCO₂ to definitively determine the accuracy of this device to deliver oxygen and measure end-tidal carbon dioxide. In addition, the ETCO₂ of the mask could be correlated to other nasal cannula products designed to measure ETCO₂ during monitored anesthesia care procedures.

REFERENCES

American Association of Nurse Anesthetists (1992). Patient monitoring standards, Guidelines and Standards for Nurse Anesthesia Practice. <u>Journal of the American</u> Association of Nurse Anesthetists, 6-7.

Asai, T. (1994). Fixation of capnograph sampling tube to a Hudson mask. Anaesthesia, 49, 745.

Barash, P. G., Cullen, B. F., & Stoelting, R. K. (1991). Acid-base and blood gases. In P.G., Barash, B.F., Cullen, & R.K., Stoelting, R. K. (Eds.), <u>Handbook of clinical</u> anesthesia (pp. 74-83). Philadelphia: J. B. Lippincott.

Burns, N., & Grove, S. K. (1997). Introduction to quantitative research. In N. Burns, N., & S.K., Grove, (Eds.). <u>The practice of nursing research: conduct, critique & utilization</u>. Philadelphia: W. B. Saunders.

Benumof, J. L. (1998). Interpretation of capnography. <u>Journal of the American</u>
Association of Nurse Anesthetists, 66, 169-176.

Bhavani-Shankar, K., Moseley, H., Kumar, A.Y., & Delph, Y. (1992). Capnography and anaesthesia. <u>Canadian Journal of Anaesthesia</u>, 39, 617-632.

Bromage, P. R. (1996). The effect of catheter position on the accuracy of end-tidal carbon dioxide measurements. <u>Anaesthesia</u>, <u>51</u>, 198.

Brunner, J.X., & Westenskow, D.R., (1988). How the rise time of carbon dioxide analysers influences the accuracy of carbon dioxide measurements. British Journal of Anaesthesia, 61, 628-638.

Campbell, F.A., McLeod, M.E., Bissonnette, B., & Swartz, J.S. (1994). End-tidal carbon dioxide measurement in infants and children during and after general anaesthesia. <u>Canadian Journal of Anaesthesia, 41(2), 107-110.</u>

Caplan, R.A., Ward, R.J., Posner, K., & Cheney, F.W. (1988). Unexpected cardiac arrest during spinal anesthesia: A closed claims analysis of predisposing factors.

<u>Anesthesiology</u>, 68, 5-11.

CAPNOXYGENTM, LLC, (1998). <u>Capnography-oxygen masks — a consistent</u> means to monitor breathing. Company product information brochure. Lebanon, TN: Author.

Derrick, S.J., Waters, H., Kang, S.W., Cwalina, T.E., & Simmons, W. (1993). Evaluation of a nasal/oral discriminate sampling system for capnographic respiratory monitoring. Journal of the American Association of Nurse Anesthetists, 61, 509-520.

From, R.P., & Schamman, F.L., (1988). Ventilatory frequency influences accuracy of end-tidal CO2 measurements. Anesthesia & Analgesia, 67, 884-886.

Fukuda, K., Ichinohe, T., & Kaneko, Y. (1997). Is measurement of end-tidal CO2 through a nasal cannula reliable? <u>Anesthesia Progress</u>, 44, 23-26.

Inomata, S., & Nishikawa, T. (1992). Early detection of airway obstruction with a capnographic probe attached to an oxygen mask. <u>Canadian Journal of Anaesthesia</u>, 39, 744.

Ivens, D., Verborgh, C., Phan Thi, H., & Camu, F. (1995). The quality of breathing and capnography during laryngeal mask and facemask ventilation. <u>Anaesthesia</u>, 50, 858-862.

Langer, R. A. (1996). Simple modification of a medium concentration (Hudson Type) oxygen mask improves patient comfort and respiratory monitoring with capnography. <u>Anesthesia & Analgesia</u>, 83, 202.

Martin, S.A. (1996). Applying nursing theory to the practice of nurse anesthesia. Journal of the American Association of Nurse Anesthetists, 64, 369-372.

Miller, B.F. (Ed.) (1992). <u>Encyclopedia and dictionary of medicine, nursing, and</u> allied health (5th ed.). Philadelphia: W.B. Saunders.

Morgan, G. E., & Mikhail, M. S. (1996). Patient monitors. In G.E. Morgan & M.S. Mikhail (Ed.), <u>Clinical Anesthesiology</u> (2nd ed., pp. 73-108). Stamford, CT: Appleton & Lange.

Murray, P. (1998). <u>The Neuman systems model: A Betty Neuman site index page</u>. Retrieved December 31, 1998 from the World Wide Web:

http://www.lemmus.demon.co.uk/neumodel.html.

NasOrCap Medical, Inc., (1998). <u>Nazorcap Sampler</u> product information web site. Retrieved December 28, 1998 from the World Wide Web:

http://www.nauticom.net/www/tfc/CAPNOGRAPY/nasorcap.html.

Oberg, B., Waldau, T., & Larsen, V. H. (1995). The effect of nasal oxygen flow and catheter position on the accuracy of end-tidal carbon dioxide measurements by a pharyngeal catheter in unintubated, spontaneously breathing subjects. <u>Anaesthesia</u>, 50, 695-698.

Risdall, J. E., & Geraghty, I. F. (1994). Respiratory monitoring in patients undergoing regional anaesthesia. Anaesthesia, 49, 179.

Saunders, M. H., Kern, N. B., Costantino, J. P., Stiller, R. A., Strollo, P. J., Studnicki, K. A., Coates, J. A., & Richards, T. J. (1994). Accuracy of end-tidal and transcutaneous PCO₂ monitoring during sleep. <u>Chest</u>, <u>106</u>, 472–483.

Szaflarski, N.L., & Cohen, N.L., (1991). Use of capnography in critically ill adults. Heart & Lung, 20, 363-374.

Takki, S., Aromaa, U. & Kauste, A. (1972). The validity and usefulness of endtidal PCO₂ during anaesthesia. <u>Annals of Clinical Research</u>, 4, 278-284.

Wren, K.R. (1994). Ventilation monitoring during monitored anesthesia care: A review. <u>Journal of the American Association of Nurse Anesthetists</u>, 62(6), 521-526.

Wright, S.W. (1992). Conscious sedation in the emergency department: The value of capnography and pulse oximetry. <u>Annals of Emergency Medicine</u>, 22(1), 551-555

APPENDICES

Appendix A. Health Survey Questionnaire

Appendix B. Informed Consent Form

Appendix C. Post-testing questionnaire

Appendix D. Data Analysis Tables by Subject.

Appendix A

Health Survey Questionnaire

Research Study THE CORRELATION BETWEEN END-TIDAL CARBON DIOXIDE MEASURED BY CAPNOXYGEN $^{\rm TM}$ MASK AND NASAL CANNULA

As you have decided to volunteer to participate in the research study identified above, please answer the following health questions to the best of you ability by circling the appropriate answer.

appropriate answer.		
1. Do you have any of the follow bronchitis, asthma, or any res rate or depth of your breathing	strictive or obstructive ill	± •
If yes, please explain bel	ow.	
2. In the last ten days, have you influenza virus?	ı had any symptoms of a YES	cold, cough, or NO
3. Do you smoke?	YES	NO
4. Do you have any limitations your nose and mouth while	¥ •	
If yes, please explain bel	ow.	
Thank you for your cooperation	in completing this guess	tionnaire

Thank you for your cooperation in completing this questionnaire.

Appendix B

Informed Consent Form

Research Study
The Correlation Between End Tidal Carbon Dioxide Measured by
CAPNOXYGENTM Mask and Nasal Cannula

Introduction

You are being asked to participate in a research study. Before you decide to a part of the research study, you need to understand the risks and benefits so that you can make an informed decision. This is known as informed consent.

This consent form provides information about the research study, which has been explained to you. Once you understand the study and the tests it requires, you will be asked to sign this form if you want to participate. Your decision to participate in the study is voluntary. This means that you are free to choose if you will take part in the study.

Purpose and Procedures

The Department of Nursing Anesthesia of the Uniformed Services University of the Health Sciences is carrying out this research study to test the accuracy of end-tidal carbon dioxide (ETCO₂) measurements obtained by a new oxygen mask produced by CAPNOXYGENTM LLC. This study will correlate these measurements to ETCO₂ measurements obtained using a carbon dioxide (CO₂) sampling port inserted inside a nasal cannula commonly used in operating rooms during conscious sedation procedures. Fifteen volunteers will be asked to participate in this research study.

The procedure for this study includes the random application of either the CAPNOXYGENTM mask over your nose and mouth, or a standard adult nasal cannula placed into your nares with a 16 gauge angiocatheter inserted through one of the prongs connected to a CO₂ sampling port. You will be asked breathe normally for two minutes to obtain baseline ETCO₂ measurements, and then oxygen will be administered in increments of 2, 4, and 6 liters per minute for a period of two minutes. At each level of oxygen administration, a average ETCO₂ reading will be taken from either the nasal catheter CO₂ sensor or CAPNOXYGENTM mask port. Following a two-minute rest period, you will be asked to breathe normally with the second devise for two minutes, and then repeat the same sequence of oxygen administration and average ETCO₂ readings. After the procedure, you will be asked to complete a brief questionnaire regarding the comfort and fit of each devise

Benefits

While there are no direct benefits to participating in the study, volunteers will be allowed to keep the CAPNOXYGENTM mask following testing.

Time Commitment

The entire procedure, including the completion of forms, should take no more than 30 minutes.

Risks

There are no risks identified in this study. The safety of nasal cannulas has been well documented in the literature. Literature from CAPNOXYGENTM LLC claims there are no contraindications for its use on human subjects.

Cost of Participation

None to you.

Alternatives

The alternative is to not participate in this research study.

Voluntariness

Participation is voluntary, refusal to participate will involve no penalty or loss of benefits, and you may discontinue participation at any time without penalty or loss of benefits. <u>Inclusion criteria</u>: Fifteen Nurse Anesthetist Student volunteers will be recruited to participate in this study. <u>Exclusion criteria</u>: Existing pulmonary disease of any kind, an upper respiratory infection within 10 days of testing, asthma, and smoking.

Research Related Injury

This study should no entail any physical or mental risk beyond those described above. We do not expect complications to occur, but if, for any reason, you feel that continuing this study would constitute a hardship for you, we will end you participation in the study.

DoD will provide medical care at government facilities for any DoD eligibles for injury or illness resulting from participation in this research. Such care may not be available to other research participants. Compensation may be available through judicial avenues to non-active duty research participants of they are injured through the negligence (fault) of the Government.

If at any time you believe you have suffered an injury or illness as a result of participating in this research project, you should contact the Office of Research Administration at the Uniformed Services University of the Health Sciences (USUHS), Bethesda, MD 20814 at (301) 295-3303. This office can review the matter with you, can provide information about your rights as a subject, and may be able to identify resources available to you. Information about judicial avenues of compensation is available from the University's General Counsel at (301) 295-3028.

Confidentiality of Records

All information that you provide as a part of this study will be confidential and will be protected to the fullest extent of the law. Information that you provide and other records related to this study will be kept private, accessible only to those persons directly involved in conducting this study and members of the Uniformed Services University of the Health Science's Institutional Review Board and other Federal agencies who provide

oversight for human use protection. All questionnaires and forms will be kept in a restricted access, locked cabinet while not in use. However, please be advised that under Federal Law, a military member s confidentiality cannot be strictly guaranteed. To enhance your privacy of the answers that you data from questionnaires will be entered into a database in which individual responses are no identified. After verification of the database information, the hard copy of the questionnaires containing identifiers will be shredded.

Questions

If you have any questions about this research study, you should contact LT Leo J. Fitzpatrick at 301-650-0009, or Maura S. McAuliffe, Ph.D., CRNA at 301-295-6565, chair of my thesis committee. If you have any questions about your rights as a research subject, you should call the Director of Research Programs in the Office of Research at USUHS at 301-295-3303. This person is your representative and has no connection to the researcher conducting this study.

I do hereby volunteer to participate in CORRELATION BETWEEN END-TIDAL (CAPNOXYGENTM MASK AND NASAL (voluntary participation: the nature, duration which it is to be conducted; and the inconventhoroughly explained to me by	CARBON DIOXIDE MEASURED BY CANNULA. The implication of my and purpose; the methods and measns by
By signing this consent form you are you and that you understand this study. You study. You will be given a copy of this conse	
I have been give the opportunity to as questions have been answered to my full and	k questions concerning this study, and such complete satisfaction.
Name (print)	Date
Signature	Date
Signature (witness)	Date
I certify that the research study has be and that the individual understands the nature benefits associated the taking part in the researaised have been answered.	
Investigator	Date

Appendix C

Post-testing questionnaire

Research Study

THE CORRELATION BETWEEN END-TIDAL CARBON DIOXIDE MEASURED BY CAPNOXYGEN TM MASK AND NASAL CANNULA

Now that you have completed your participation in the study identified above, please answer the following questions regarding the comfort and fit of each devise used.

- 1. Which devise was more comfortable to wear during your testing experience? Why?
- 2. If this had been a conscious sedation or monitored anesthesia care procedure lasting more than one hour, which devise would you prefer to wear?
- 3. In your opinion, which devise provided the best fit for administering oxygen and measuring end-tidal carbon dioxide?
 - 4. At rest, would you describe yourself as a nose breather or mouth breather?
- 5. When wearing the nasal cannula, did you deliberately try to breathe through your nose?

Any additional comments regarding your testing procedure?



DEVICE: Nasal Cannula

DEVICE: Na				1 = =	
O ₂ L/M	TIME sec	FIO ₂	SaO ₂	RR	ETCO ₂
	30	21	95	18	42
0	60	21	96	16	43
	90	21	96	16	44
	120	21	97	16	42
	AVE.				42.75
	30	22	97	28	44
2	60	22	98	16	43
	90	22	98	16	44
	120	23	98	16	44
	AVE.				43.75
	30	30	99	15	44
4	60	34	99	15	43
	90	29	99	16	42
	120	30	99	16	43
	AVE.				43
	30	39	98	17	42
6	60	40	99	16	42
	90	37	99	16	43
	120	36	99	16	42
	AVE.				42.25
O ₂ L/M		FIO ₂	SAO ₂	RR	42.25 ETCO ₂
O ₂ L/M	AVE. TIME sec	FIO ₂	SAO ₂	RR 15	42.25 ETCO ₂ 42
	TIME sec		96	15	ETCO ₂
O ₂ L/M	TIME sec	21	1		ETCO ₂ 42
	TIME sec 30 60	21 18	96 95	15 16	ETCO ₂ 42 40
	TIME sec 30 60 90	21 18 19	96 95 96	15 16 14	ETCO ₂ 42 40 41
	TIME sec 30 60 90 120	21 18 19	96 95 96	15 16 14	ETCO ₂ 42 40 41 41
	TIME sec 30 60 90 120 AVE	21 18 19 19	96 95 96 95	15 16 14 15	ETCO ₂ 42 40 41 41
0	TIME sec 30 60 90 120 AVE 30 60	21 18 19 19 27 28	96 95 96 95 95 95	15 16 14 15 16 14	ETCO ₂ 42 40 41 41 41 39 39
0	TIME sec 30 60 90 120 AVE 30	21 18 19 19 27	96 95 96 95 95	15 16 14 15	ETCO ₂ 42 40 41 41 41 39
0	TIME sec 30 60 90 120 AVE 30 60 90	21 18 19 19 27 28 28	96 95 96 95 95 95 95 98	15 16 14 15 16 14 14	ETCO ₂ 42 40 41 41 41 39 39 38
0	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE	21 18 19 19 27 28 28 28	96 95 96 95 95 95 95 98 98	15 16 14 15 16 14 14 14	ETCO ₂ 42 40 41 41 41 39 39 38 37 38.25
0	TIME sec 30 60 90 120 AVE 30 60 90 120	21 18 19 19 27 28 28	96 95 96 95 95 95 95 98	15 16 14 15 16 14 14	ETCO ₂ 42 40 41 41 41 39 39 38 37
2	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE	21 18 19 19 27 28 28 28 28 29	96 95 96 95 95 95 95 98 98	15 16 14 15 16 14 14 14 14	ETCO ₂ 42 40 41 41 41 39 39 38 37 38.25 37
2	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE	21 18 19 19 27 28 28 28 32	96 95 96 95 95 95 95 98 98 98	15 16 14 15 16 14 14 14 14 18	ETCO ₂ 42 40 41 41 41 39 39 38 37 38.25 37 36 34
2	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE	21 18 19 19 27 28 28 28 28 28 32 29 33	96 95 96 95 95 95 98 98 98 98	15 16 14 15 16 14 14 14 14 18 14 15	ETCO ₂ 42 40 41 41 41 39 39 38 37 38.25 37 36 34 36
2	TIME sec 30 60 90 120 AVE	21 18 19 19 27 28 28 28 28 28 32 29 33 29	96 95 96 95 95 95 98 98 98 98 98	15 16 14 15 16 14 14 14 14 18 14 15 13	ETCO ₂ 42 40 41 41 41 39 39 38 37 38.25 37 36 34 36 35.75
2	TIME sec 30 60 90 120 AVE	21 18 19 19 27 28 28 28 28 32 29 33 29	96 95 96 95 95 95 98 98 98 98 99 99	15 16 14 15 16 14 14 14 14 15 13	ETCO ₂ 42 40 41 41 41 39 39 38 37 38.25 37 36 34 36 35.75 34
2	TIME sec 30 60 90 120 AVE	21 18 19 19 27 28 28 28 28 29 33 29 36 37	96 95 96 95 95 95 98 98 98 98 99 99	15 16 14 15 16 14 14 14 14 15 13	ETCO ₂ 42 40 41 41 41 39 39 38 37 38.25 37 36 34 36 35.75 34
2	TIME sec 30 60 90 120 AVE	21 18 19 19 27 28 28 28 28 32 29 33 29 36 37 34	96 95 96 95 95 95 98 98 98 98 99 99 99	15 16 14 15 16 14 14 14 14 15 13 14 15 15	ETCO ₂ 42 40 41 41 41 39 39 38 37 38.25 37 36 34 36 35.75 34 35 32
2	TIME sec 30 60 90 120 AVE	21 18 19 19 27 28 28 28 28 29 33 29 36 37	96 95 96 95 95 95 98 98 98 98 99 99	15 16 14 15 16 14 14 14 14 15 13	ETCO ₂ 42 40 41 41 41 39 39 38 37 38.25 37 36 34 36 35.75 34

<u>Data analysis table (per subject)</u> <u>Subject #2</u>

DEVICE: CAPNOXYGEN mask

O ₂ L/M	TIME sec	FIO	SaO ₂	RR	ETCO ₂
O ₂ L/IVI	30	21	99	10	42
0	60	21	99	13	42
	90	21	99	12	39
	120	21	100	22	40
	AVE.	21	100		40.75
	30	30	100	8	39
2	60	30	100	8	37
_	90	28	100	10	35
	120	28	100	13	29
	AVE.		100		35
	30	34	100	9	36
4	60	46	100	6	37
	90	37	100	7	36
	120	36	100	5	36
	AVE.				36.25
	30	44	100	18	35
6	60	33	100	14	33
	90	43	100	21	28
	120	46	100	7	34
	AVE.				32.5
O ₂ L/M	TIME sec	FIO ₂	SAO ₂	RR	ETCO ₂
			- · · · <u>-</u>		
	30	21	99	22	36
0					
	30	21	99	22	36
	30 60	21 21	99 99	22 24	36 38
	30 60 90	21 21 20 21	99 99 99	22 24 22	36 38 35
0	30 60 90 120	21 21 20	99 99 99	22 24 22	36 38 35 36
	30 60 90 120 AVE 30 60	21 21 20 21 23 24	99 99 99 99	22 24 22 18 8 7	36 38 35 36 36.25 39
0	30 60 90 120 AVE 30	21 21 20 21 23	99 99 99 99	22 24 22 18	36 38 35 36 36.25 39
0	30 60 90 120 AVE 30 60	21 21 20 21 23 24	99 99 99 99 99 100	22 24 22 18 8 7	36 38 35 36 36.25 39
0	30 60 90 120 AVE 30 60	21 20 21 23 24 27 23	99 99 99 99 99 100 100	22 24 22 18 8 7 9	36 38 35 36 36.25 39 39
2	30 60 90 120 AVE 30 60 90	21 21 20 21 23 24 27	99 99 99 99 100 100	22 24 22 18 8 7 9	36 38 35 36 36.25 39 39 39
0	30 60 90 120 AVE 30 60 90 120 AVE 30 60	21 20 21 23 24 27 23 31 33	99 99 99 99 100 100 100 100	22 24 22 18 8 7 9 8	36 38 35 36 36.25 39 39 39 39 39 39
2	30 60 90 120 AVE 30 60 90 120 AVE 30 60 90	21 20 21 23 24 27 23 31 33 24	99 99 99 99 100 100 100 100 100	22 24 22 18 8 7 9 8 8 10 9	36 38 35 36 36.25 39 39 39 39 39 39 39
2	30 60 90 120 AVE 30 60 90 120 AVE 30 60 90	21 20 21 23 24 27 23 31 33	99 99 99 99 100 100 100 100	22 24 22 18 8 7 9 8	36 38 35 36 36.25 39 39 39 39 39 39 40 40
2	30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE	21 20 21 23 24 27 23 31 33 24 47	99 99 99 99 100 100 100 100 100 100	22 24 22 18 8 7 9 8 10 9 8	36 38 35 36 36.25 39 39 39 39 39 39 40 40 40 38
2	30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE 30	21 20 21 23 24 27 23 31 33 24 47	99 99 99 99 100 100 100 100 100 100	22 24 22 18 8 7 9 8 10 9	36 38 35 36 36.25 39 39 39 39 39 39 40 40 40 38 40
2	30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE 30 60	21 21 20 21 23 24 27 23 31 33 24 47 25 24	99 99 99 99 100 100 100 100 100 100 100	22 24 22 18 8 7 9 8 10 9 8	36 38 35 36 36.25 39 39 39 39 39 39 40 40 40 38 40 38
2	30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE 30 60 90	21 21 20 21 23 24 27 23 31 33 24 47 25 24 33	99 99 99 99 100 100 100 100 100 100 100	22 24 22 18 8 7 9 8 10 9 8	36 38 35 36 36.25 39 39 39 39 39 39 39 39 39 39
2	30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE 30 60	21 21 20 21 23 24 27 23 31 33 24 47 25 24	99 99 99 99 100 100 100 100 100 100 100	22 24 22 18 8 7 9 8 10 9 8	36 38 35 36 36.25 39 39 39 39 39 39 40 40 40 38 40 38

<u>Data analysis table (per subject)</u> <u>Subject # 3</u>

<u>DEVICE</u>: CAPNOXYGEN mask

O ₂ L/M	TIME sec		SaO ₂	RR	ETCO ₂
02 =/ IVI	30	21	98	13	43
0	60	21	98	16	34
	90	20	98	13	37
	120	21	98	8	41
	AVE.				38.75
	30	24	99	7	37
2	60	24	99	7	37
_	90	22	99	9	39
	120	24	99	8	38
	AVE.				37.75
	30	30	100	7	34
4	60	28	100	17	32
	90	27	100	16	30
	120	25	100	9	31
	AVE.				31.75
	30	28	100	16	32
6	60	39	100	17	32
	90	30	100	10	32
	120	30	100	16	33
	AVE.	00	100	10	32.25
	AVE				1.37.73
O ₂ L/M		FIO ₂	SAO ₂	RR	
O ₂ L/M	TIME sec	FIO ₂	SAO ₂	RR 15	ETCO ₂
	TIME sec	21	99	15	ETCO ₂ 35
O ₂ L/M	TIME sec	21 21		15 23	35 38
	TIME sec 30 60	21	99 99	15	ETCO ₂ 35
	TIME sec 30 60 90	21 21 21	99 99 98	15 23 22	35 38 37
	TIME sec 30 60 90 120	21 21 21	99 99 98	15 23 22	35 38 37 37
	TIME sec 30 60 90 120 AVE	21 21 21 21	99 99 98 99	15 23 22 14	35 38 37 37 36.75
0	TIME sec 30 60 90 120 AVE 30	21 21 21 21 21	99 99 98 99	15 23 22 14	35 38 37 37 36.75
0	TIME sec 30 60 90 120 AVE 30 60	21 21 21 21 21 21	99 99 98 99 99	15 23 22 14 22 11	35 38 37 37 36.75 36 32
0	TIME sec 30 60 90 120 AVE 30 60 90	21 21 21 21 21 21 21	99 98 99 99 99	15 23 22 14 22 11 19	ETCO ₂ 35 38 37 37 36.75 36 32 31
0	TIME sec 30 60 90 120 AVE 30 60 90 120	21 21 21 21 21 21 21	99 98 99 99 99	15 23 22 14 22 11 19	ETCO ₂ 35 38 37 37 36.75 36 32 31 38
0	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE	21 21 21 21 21 21 21 21	99 98 99 99 99 99 99	15 23 22 14 22 11 19 14	ETCO ₂ 35 38 37 37 36.75 36 32 31 38 34.25
2	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE	21 21 21 21 21 21 21 21 21	99 99 98 99 99 99 99 99	15 23 22 14 22 11 19 14	ETCO ₂ 35 38 37 37 36.75 36 32 31 38 34.25 40
2	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE	21 21 21 21 21 21 21 21 22 24	99 98 99 99 99 99 99 100	15 23 22 14 22 11 19 14	ETCO ₂ 35 38 37 37 36.75 36 32 31 38 34.25 40 37
2	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 100 AVE	21 21 21 21 21 21 21 21 21 22 24 23	99 99 98 99 99 99 99 99 100 100	15 23 22 14 22 11 19 14 19 13 20	ETCO ₂ 35 38 37 37 36.75 36 32 31 38 34.25 40 37
2	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE	21 21 21 21 21 21 21 21 21 22 24 23	99 99 98 99 99 99 99 99 100 100	15 23 22 14 22 11 19 14 19 13 20	ETCO ₂ 35 38 37 37 36.75 36 32 31 38 34.25 40 37 36 39
2	TIME sec 30 60 90 120 AVE	21 21 21 21 21 21 21 21 21 22 24 23 25	99 99 98 99 99 99 99 100 100 100 99	15 23 22 14 22 11 19 14 19 13 20 14	ETCO ₂ 35 38 37 37 36.75 36 32 31 38 34.25 40 37 36 39 38
2	TIME sec 30 60 90 120 AVE	21 21 21 21 21 21 21 21 22 24 23 25	99 99 98 99 99 99 99 99 100 100 100 99	15 23 22 14 22 11 19 14 19 13 20 14	ETCO ₂ 35 38 37 37 36.75 36 32 31 38 34.25 40 37 36 39 38 41
2	TIME sec 30 60 90 120 AVE	21 21 21 21 21 21 21 21 22 24 23 25	99 99 98 99 99 99 99 99 100 100 99	15 23 22 14 22 11 19 14 19 13 20 14 15 30	ETCO ₂ 35 38 37 37 36.75 36 32 31 38 34.25 40 37 36 39 38 41 37

DEVICE: CAPNOXYGEN mask

O ₂ L/M	TIME sec		SaO ₂	RR	ETCO ₂
<u> </u>	30	21	100	17	40
0	60	21	100	21	38
	90	21	100	13	41
	120	21	100	14	41
	AVE.	<u> </u>	100	17	40
	30	28	100	10	38
2	60	27	100	10	39
					38
	90	29	100	10	
	120	29	100	10	39
	AVE.	0.5	400	4.4	38.5
4	30	35	100	11	36
4	60	42	100	8	37
	90	40	100	8	36
	120	35	100	10	35
	AVE.				36
	30	33	100	12	34
6	60	43	100	8	35
	90	43	100	7	35
	120	34	100	10	34
	AVE.				34.5
O ₂ L/M	TIME sec	FIO ₂	SAO ₂	RR	ETCO ₂
	30	21	100	12	38
0	60	21	100	13	40
	90	21	100	15	38
	120	21	100	19	40
	AVE				39
	30	22	100	12	41
2	60	23	100	13	41
	90	29	100	13	42
	120	22	100	11	40
	AVE				41
	/ \ \ \				-
Ī	30	39	100	10	40
4		39 32	100	10	
4	30				40
4	30 60	32	100	14	40 40
4	30 60 90	32 33	100 100	14 12	40 40 41
4	30 60 90 120	32 33	100 100	14 12	40 40 41 42
	30 60 90 120 AVE	32 33 39	100 100 100	14 12 11	40 40 41 42 40.25
6	30 60 90 120 AVE 30	32 33 39 49	100 100 100 100	14 12 11 12 9	40 40 41 42 40.25 41
	30 60 90 120 AVE 30 60	32 33 39 49	100 100 100 100 100	14 12 11 12	40 40 41 42 40.25 41

DEVICE: Nasal Cannula

O ₂ L/M	TIME sec	FIO	SaO ₂	RR	ETCO ₂
O ₂ L/IVI	30	21	100	18	38
0	60	21	100	15	37
	90	21	100	14	41
	120	21	100	15	40
		Z I	100	10	
	AVE.	20	400	47	39
2	30	30	100	17	37
2	60	30	100	11	38
	90	21	100	17	39
	120	22	100	25	41
	AVE.	0.4	400		38.75
	30	21	100	11	37
4	60	23	100	6	40
	90	25	100	8	44
	120	41	100	7	44
	AVE.				41.25
	30	34	100	9	42
6	60	46	100	9	43
	90	43	100	9	44
	120	44	100	9	36
	AVE.				41.25
O ₂ L/M	TIME sec	FIO ₂	SAO ₂	RR	ETCO ₂
	30	21	100	12	41
0	60	21	100	8	43
	90	21	100	8	44
		00	400		
	120	20	100	12	39
	AVE	20	100	12	39 41.75
		26	100	13	
2	AVE				41.75
2	AVE 30	26	100	13	41.75 37
2	AVE 30 60	26 43	100 100	13 10	41.75 37 38
2	AVE 30 60 90	26 43 31	100 100 100	13 10 5	41.75 37 38 43
2	AVE 30 60 90 120	26 43 31	100 100 100	13 10 5	41.75 37 38 43 37
2	AVE 30 60 90 120 AVE	26 43 31 27	100 100 100 100	13 10 5 16	41.75 37 38 43 37 38.25
	AVE 30 60 90 120 AVE 30	26 43 31 27	100 100 100 100	13 10 5 16	41.75 37 38 43 37 38.25 41
	AVE 30 60 90 120 AVE 30 60	26 43 31 27 31 34	100 100 100 100 100	13 10 5 16 7	41.75 37 38 43 37 38.25 41
	AVE 30 60 90 120 AVE 30 60 90	26 43 31 27 31 34 39	100 100 100 100 100 100 100	13 10 5 16 7 7 8	41.75 37 38 43 37 38.25 41 40 41
	AVE 30 60 90 120 AVE 30 60 90 120	26 43 31 27 31 34 39	100 100 100 100 100 100 100	13 10 5 16 7 7 8	41.75 37 38 43 37 38.25 41 40 41 42
4	AVE 30 60 90 120 AVE 30 60 90 120 AVE	26 43 31 27 31 34 39 40	100 100 100 100 100 100 100 100	13 10 5 16 7 7 8 8	41.75 37 38 43 37 38.25 41 40 41 42 41
	AVE 30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE	26 43 31 27 31 34 39 40	100 100 100 100 100 100 100 100 100	13 10 5 16 7 7 8 8	41.75 37 38 43 37 38.25 41 40 41 42 41 40
4	AVE 30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE	26 43 31 27 31 34 39 40 33 35	100 100 100 100 100 100 100 100	13 10 5 16 7 7 8 8	41.75 37 38 43 37 38.25 41 40 41 42 41 40 37

<u>Data analysis table (per subject)</u> <u>Subject # 6</u>

O ₂ L/M	TIME sec	FIO ₂	SaO ₂	RR	ETCO ₂
	30	20	98	12	46
0	60	20	98	18	40
	90	20	99	15	42
	120	20	98	14	41
	AVE.				42.25
	30	23	99	13	42
2	60	21	99	17	41
	90	21	100	15	40
	120	23	99	16	40
	AVE.				40.75
	30	30	100	14	41
4	60	27	100	13	40
	90	29	100	6	41
	120	29	100	15	45
	AVE.				41.75
	30	34	100	14	42
6	60	32	100	12	42
	90	33	100	14	42
	120	33	100	9	41
	A \ / 🗔		1		40.5
	AVE.				42.5
O ₂ L/M	TIME sec	FIO ₂	SAO ₂	RR	ETCO ₂
O ₂ L/M		FIO ₂	SAO ₂	RR 13	
O ₂ L/M	TIME sec	21 20	100 100		ETCO ₂ 40 39
	TIME sec 30 60 90	21 20 20	100 100 100	13 18 13	ETCO ₂ 40 39 42
	TIME sec 30 60 90 120	21 20	100 100	13 18	ETCO ₂ 40 39 42 41
	TIME sec 30 60 90 120 AVE	21 20 20 21	100 100 100 100	13 18 13 11	ETCO ₂ 40 39 42 41 40.5
0	TIME sec 30 60 90 120 AVE 30	21 20 20 21 25	100 100 100 100	13 18 13 11	ETCO ₂ 40 39 42 41 40.5 36
	TIME sec 30 60 90 120 AVE 30 60	21 20 20 21 25 27	100 100 100 100 100	13 18 13 11 12 14	ETCO ₂ 40 39 42 41 40.5 36 37
0	TIME sec 30 60 90 120 AVE 30 60 90	21 20 20 21 25 27 26	100 100 100 100 100 100 100	13 18 13 11 12 14 10	ETCO ₂ 40 39 42 41 40.5 36 37 35
0	TIME sec 30 60 90 120 AVE 30 60 90 120	21 20 20 21 25 27	100 100 100 100 100	13 18 13 11 12 14	ETCO ₂ 40 39 42 41 40.5 36 37 35 37
0	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE	21 20 20 21 25 27 26 27	100 100 100 100 100 100 100 100	13 18 13 11 12 14 10 15	ETCO ₂ 40 39 42 41 40.5 36 37 35 37 36.25
2	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE	21 20 20 21 25 27 26 27	100 100 100 100 100 100 100 100	13 18 13 11 12 14 10 15	ETCO ₂ 40 39 42 41 40.5 36 37 35 37 36.25 35
0	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE	21 20 20 21 25 27 26 27 32 30	100 100 100 100 100 100 100 100	13 18 13 11 12 14 10 15	ETCO ₂ 40 39 42 41 40.5 36 37 35 37 36.25 35 35
2	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 100 AVE	21 20 20 21 25 27 26 27 32 30 39	100 100 100 100 100 100 100 100 100 100	13 18 13 11 12 14 10 15 15 10 14	ETCO ₂ 40 39 42 41 40.5 36 37 35 37 36.25 35 35 35
2	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE	21 20 20 21 25 27 26 27 32 30	100 100 100 100 100 100 100 100	13 18 13 11 12 14 10 15	ETCO ₂ 40 39 42 41 40.5 36 37 35 37 36.25 35 35 35 37
2	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE 30 AVE 30 AVE 30 AVE	21 20 20 21 25 27 26 27 32 30 39 32	100 100 100 100 100 100 100 100 100 100	13 18 13 11 12 14 10 15 15 10 14 12	ETCO ₂ 40 39 42 41 40.5 36 37 35 37 36.25 35 35 37 35.5
2	TIME sec 30 60 90 120 AVE	21 20 20 21 25 27 26 27 32 30 39 32	100 100 100 100 100 100 100 100 100 100	13 18 13 11 12 14 10 15 15 10 14 12	ETCO ₂ 40 39 42 41 40.5 36 37 35 37 36.25 35 35 35 37 35.5 37
2	TIME sec 30 60 90 120 AVE	21 20 20 21 25 27 26 27 32 30 39 32 40 41	100 100 100 100 100 100 100 100 100 100	13 18 13 11 12 14 10 15 15 10 14 12 10	ETCO ₂ 40 39 42 41 40.5 36 37 35 37 36.25 35 35 35 37 35.5 37 35.5
2	TIME sec 30 60 90 120 AVE	21 20 20 21 25 27 26 27 32 30 39 32 40 41 38	100 100 100 100 100 100 100 100 100 100	13 18 13 11 12 14 10 15 15 10 14 12 10 14 12	ETCO ₂ 40 39 42 41 40.5 36 37 35 37 36.25 35 35 35 37 35.5 35 37 35.5 33
2	TIME sec 30 60 90 120 AVE	21 20 20 21 25 27 26 27 32 30 39 32 40 41	100 100 100 100 100 100 100 100 100 100	13 18 13 11 12 14 10 15 15 10 14 12 10	ETCO ₂ 40 39 42 41 40.5 36 37 35 37 36.25 35 35 35 37 35.5 37 35.5

DEVICE: CAPNOXYGEN mask

O ₂ L/M	TIME sec		SaO ₂	RR	ETCO ₂
<u> </u>	30	20	98	15	40
0	60	21	100	17	40
Ŭ	90	20	100	12	42
	120	21	100	11	43
	AVE.		100	1 1	41.25
	30	30	100	11	37
2	60	29	100	16	35
	90	31	100	10	37
	120	32	100	11	36
	AVE.	32	100	11	36.25
	30	22	100	15	
4		33	100		35
4	60	33	100	14	34
	90	33	100	15	34
	120	34	100	11	34
	AVE.				34.25
	30	35	100	14	31
6	60	37	100	14	30
	90	36	100	16	30
	120	37	100	17	31
	AVE.				30.50
O ₂ L/M	TIME sec	FIO ₂	SAO ₂	RR	ETCO ₂
	30	20	99	15	39
0	60	21	99	19	40
	90	21	99	18	36
	120	20	99	20	41
	AVE				39
	30	24	100	17	40
2	60	24	100	10	20
		– 1	100	19	38
	90	23	100	13	41
	90	23	100	13	41
	90 120	23	100	13	41 39
4	90 120 AVE	23 22	100	13 19	41 39 39.5
4	90 120 AVE 30	23 22 47	100 100 100	13 19 13	41 39 39.5 38
4	90 120 AVE 30 60	23 22 47 41	100 100 100 100	13 19 13 21	41 39 39.5 38 39
4	90 120 AVE 30 60 90	23 22 47 41 44	100 100 100 100 100	13 19 13 21 17	41 39 39.5 38 39 36 34
4	90 120 AVE 30 60 90 120 AVE	23 22 47 41 44	100 100 100 100 100 100	13 19 13 21 17	41 39 39.5 38 39 36
	90 120 AVE 30 60 90 120	23 22 47 41 44 38	100 100 100 100 100	13 19 13 21 17 21	41 39 39.5 38 39 36 34 36.75
6	90 120 AVE 30 60 90 120 AVE 30	23 22 47 41 44 38 56 67	100 100 100 100 100 100 100	13 19 13 21 17 21 19	41 39 39.5 38 39 36 34 36.75 28
	90 120 AVE 30 60 90 120 AVE 30 60	23 22 47 41 44 38	100 100 100 100 100 100	13 19 13 21 17 21	41 39 39.5 38 39 36 34 36.75 28

DEVICE: Nasal Cannula

O ₂ L/M	TIME sec	FIO ₂	SaO ₂	RR	ETCO ₂
O ₂ E/W	30	21	100	8	38
0	60	21	100	8	38
	90	21	100	9	39
	120	21	100	8	40
	AVE.	Z I	100	0	38.75
		22	100	10	
2	30	23	100	10	40
2	60	23	100	8	40
	90	24	100	8	39
	120	23	100	8	41
	AVE.	00	100	10	40
	30	28	100	10	37
4	60	49	100	11	40
	90	33	100	13	39
	120	28	100	13	39
	AVE.				38.75
	30	46	100	9	37
6	60	58	100	9	37
	90	50	100	13	37
	120	47	100	8	39
	AVE.				37.5
O ₂ L/M	TIME sec	FIO ₂	SAO ₂	RR	ETCO ₂
	30	20	99	17	37
0	60	20	99	16	42
	00				
	90	20	99	15	41
		20	99	15 15	41 42
	90				
	90 120				42
2	90 120 AVE	20	99	15	42 40.5
2	90 120 AVE 30	20	99	15 13	42 40.5 36
2	90 120 AVE 30 60	29 30	99 99 100	15 13 10	42 40.5 36 36
2	90 120 AVE 30 60 90	29 30 29	99 99 100 100	15 13 10 8	42 40.5 36 36 37
2	90 120 AVE 30 60 90 120	29 30 29	99 99 100 100	15 13 10 8	42 40.5 36 36 37 36
2	90 120 AVE 30 60 90 120 AVE	29 30 29 30	99 99 100 100 100	15 13 10 8 14	42 40.5 36 36 37 36 36.25
	90 120 AVE 30 60 90 120 AVE 30	29 30 29 30 46	99 99 100 100 100	15 13 10 8 14	42 40.5 36 36 37 36 36 36.25 34
	90 120 AVE 30 60 90 120 AVE 30 60	29 30 29 30 46 47	99 99 100 100 100 100	15 13 10 8 14 11	42 40.5 36 36 37 36 36.25 34 35
	90 120 AVE 30 60 90 120 AVE 30 60 90	29 30 29 30 46 47 35	99 100 100 100 100 100 100	15 13 10 8 14 11 11 12	42 40.5 36 37 36 36.25 34 35 34
	90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE	29 30 29 30 46 47 35	99 100 100 100 100 100 100 100	15 13 10 8 14 11 11 12	42 40.5 36 37 36 36.25 34 35 34 34 34.25
4	90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE 30	29 30 29 30 46 47 35 42	99 100 100 100 100 100 100 100	15 13 10 8 14 11 11 12 15	42 40.5 36 37 36 36.25 34 35 34 34 34 34.25 29
	90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE 30 60	29 30 29 30 46 47 35 42 45 46	99 100 100 100 100 100 100 100 100	15 13 10 8 14 11 11 12 15	42 40.5 36 37 36 36.25 34 35 34 34 34.25 29 31
4	90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE 30	29 30 29 30 46 47 35 42	99 100 100 100 100 100 100 100	15 13 10 8 14 11 11 12 15	42 40.5 36 37 36 36.25 34 35 34 34 34 34.25 29

DEVICE: Nasal Cannula

O_2 L/M	TIME sec	FIO.	SaO ₂	RR	ETCO ₂
O ₂ L/IVI			97	15	42
	30	20			
0	60	21	96 97	9	43
	90	21			45
	120	21	97	10	44
	AVE.	00	00	40	43.5
	30	23	98	10	44
2	60	21	99	8	44
	90	23	99	8	43
	120	22	99	9	44
	AVE.				43.25
	30	24	99	9	44
4	60	23	99	8	46
	90	23	99	10	44
	120	24	99	11	46
	AVE.				45
	30	24	99	12	43
6	60	27	100	14	43
	90	36	100	11	45
	120	25	99	18	42
	AVE.				43.25
O ₂ L/M	TIME sec	FIO ₂	SAO ₂	RR	ETCO ₂
	30	20	96	17	41
•					
0	60	20	97	14	42
0	60 90	20 21	97 97	14 14	42 42
0					
0	90	21	97	14	42
	90 120	21	97	14	42 42
2	90 120 AVE	21 20	97 98	14	42 42 41.25
	90 120 AVE 30	21 20 27	97 98 97	14 10	42 42 41.25 37
	90 120 AVE 30 60	21 20 27 32	97 98 97 98	14 10 14 15	42 42 41.25 37 37
	90 120 AVE 30 60 90	21 20 27 32 31	97 98 97 98 98	14 10 14 15 13	42 42 41.25 37 37 35
	90 120 AVE 30 60 90 120	21 20 27 32 31	97 98 97 98 98	14 10 14 15 13	42 42 41.25 37 37 35 37
	90 120 AVE 30 60 90 120 AVE	21 20 27 32 31 32	97 98 97 98 98 98	14 10 14 15 13 11	42 42 41.25 37 37 35 37 36.25
2	90 120 AVE 30 60 90 120 AVE 30	21 20 27 32 31 32 35	97 98 97 98 98 98 99	14 10 14 15 13 11	42 42 41.25 37 37 35 37 36.25 34
2	90 120 AVE 30 60 90 120 AVE 30 60	21 20 27 32 31 32 35 33	97 98 97 98 98 98 99	14 10 14 15 13 11 19	42 42 41.25 37 37 35 37 36.25 34 35
2	90 120 AVE 30 60 90 120 AVE 30 60 90	21 20 27 32 31 32 35 33 35	97 98 97 98 98 98 99 99	14 10 14 15 13 11 19 13 16	42 42 41.25 37 37 35 37 36.25 34 35 33
2	90 120 AVE 30 60 90 120 AVE 30 60 90 120	21 20 27 32 31 32 35 33 35	97 98 97 98 98 98 99 99	14 10 14 15 13 11 19 13 16	42 42 41.25 37 37 35 37 36.25 34 35 33 34
2	90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE	21 20 27 32 31 32 35 33 35 48	97 98 97 98 98 98 99 99 100 99	14 10 14 15 13 11 19 13 16 12	42 42 41.25 37 37 35 37 36.25 34 35 33 34 34
4	90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE 30	21 20 27 32 31 32 35 33 35 48	97 98 97 98 98 98 99 99 100 99	14 10 14 15 13 11 19 13 16 12	42 41.25 37 37 35 37 36.25 34 35 33 34 34 34 32
4	90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE 30 60	21 20 27 32 31 32 35 33 35 48 36 46	97 98 97 98 98 99 99 100 99 97 98	14 10 14 15 13 11 19 13 16 12 16 13	42 42 41.25 37 37 35 37 36.25 34 35 33 34 34 32 30

DEVICE: Nasal Cannula

O_2 L/M	TIME sec	FIO	SaO ₂	RR	ETCO ₂
O ₂ L/IVI	30	21	100	17	35
0	60	21	100	13	37
	90	21	100	15	37
	120	21	100	11	36
	AVE.	Z I	100	11	
		00	100	10	36.25
2	30	23	100	10	39
2	60	22	100	11	37
	90	23	100	9	40
	120	22	100	10	38
	AVE.	00	400		38.5
4	30	23	100	9	39
4	60	24	100	9	37
	90	25	100	9	38
	120	24	100	9	40
	AVE.				38.5
	30	30	100	9	39
6	60	26	100	12	37
	90	37	100	7	38
	120	28	100	10	37
	AVE.				37.75
O ₂ L/M	TIME sec	FIO ₂	SAO ₂	RR	ETCO ₂
	30	21	100	13	36
I 0	60	21	100	15	35
0	60				
	90	21	100	14	36
U	90	21	100	14	36
	90 120	21	100	14	36 35
2	90 120 AVE	21 21	100	14 12	36 35 35.5
	90 120 AVE 30	21 21 23	100 100 100	14 12 18	36 35 35.5 33
	90 120 AVE 30 60	21 21 23 31	100 100 100 100	14 12 18 12	36 35 35.5 33 32
	90 120 AVE 30 60 90	21 21 23 31 27	100 100 100 100 100	14 12 18 12 12	36 35 35.5 33 32 33
	90 120 AVE 30 60 90 120	21 21 23 31 27	100 100 100 100 100	14 12 18 12 12	36 35 35.5 33 32 33 32
	90 120 AVE 30 60 90 120 AVE	21 21 23 31 27 27	100 100 100 100 100 100	14 12 18 12 12 12	36 35 35.5 33 32 33 32 32.5
2	90 120 AVE 30 60 90 120 AVE 30	21 21 23 31 27 27 37	100 100 100 100 100 100	14 12 18 12 12 12 12	36 35 35.5 33 32 33 32 32.5 33
2	90 120 AVE 30 60 90 120 AVE 30 60	21 21 23 31 27 27 27 37 38	100 100 100 100 100 100 100	14 12 18 12 12 12 12 17	36 35 35.5 33 32 33 32 32.5 33 31
2	90 120 AVE 30 60 90 120 AVE 30 60 90	21 21 23 31 27 27 27 37 38 38	100 100 100 100 100 100 100 100	14 12 18 12 12 12 12 17 11 14	36 35 35.5 33 32 33 32 32.5 33 31 32
2	90 120 AVE 30 60 90 120 AVE 30 60 90 120	21 21 23 31 27 27 27 37 38 38	100 100 100 100 100 100 100 100	14 12 18 12 12 12 12 17 11 14	36 35 35.5 33 32 33 32 32.5 33 31 32 30
2	90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE	21 21 23 31 27 27 27 37 38 38 38	100 100 100 100 100 100 100 100 100	14 12 18 12 12 12 12 17 11 14 17	36 35 35.5 33 32 33 32 32.5 33 31 32 30 31.5
4	90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE 30	21 21 23 31 27 27 27 37 38 38 38	100 100 100 100 100 100 100 100 100	14 12 18 12 12 12 12 17 11 14 17	36 35 35.5 33 32 33 32 32.5 33 31 32 30 31.5 30
4	90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE 30 60	21 21 23 31 27 27 27 37 38 38 38 38	100 100 100 100 100 100 100 100 100 100	14 12 18 12 12 12 12 17 11 14 17	36 35 35.5 33 32 33 32 32.5 33 31 32 30 31.5 30 29

<u>Data analysis table (per subject)</u> <u>Subject # 11</u>

DEVICE: CAPNOXYGEN mask

O ₂ L/M	TIME sec		SaO ₂	RR	ETCO ₂
OZ E/IVI	30	20	99	20	37
0	60	20	99	11	41
	90	20	100	12	40
	120	20	100	13	41
	AVE.	20	100	10	36.25
	30	26	100	19	37
2	60	27	100	9	37
	90	29	100	15	31
	120	28	100	13	37
	AVE.	20	100	13	35.5
	30	35	100	8	34
4	60			15	
4		36	100		35
	90	32	100	8	34
	120	33	100	12	33
	AVE.		400	1.0	34
	30	36	100	12	32
6	60	42	100	14	31
	90	39	100	12	31
	120	40	100	18	30
	AVE.				31.5
O ₂ L/M	TIME sec	FIO ₂	SAO ₂	RR	ETCO ₂
	30	21	100	12	38
0	60	20	100	15	33
	90	21	100	11	39
	120	21	100	16	36
	AVE				36.5
	30	24	100	12	40
2	60	23	100	11	36
	90	24	100	10	36
	120	22	100	12	39
	AVE				37.75
	30	23	100	17	37
4	60	31	100	9	39
ī	90	44	100	19	39
		44 67	100	19 21	39 37
	90				
	90 120				37
6	90 120 AVE	67	100	21	37 38
6	90 120 AVE 30	67 56	100	10	37 38 36
6	90 120 AVE 30 60	56 40	100 100 100	10 20	37 38 36 31

DEVICE: CAPNOXYGEN mask

DEVICE: CA	TIME sec		SaO-	RR	ETCO ₂
O ₂ L/M	+		SaO ₂		
	30	21	97	12	45
0	60	21	96	13	44
	90	21	96	10	46
	120	21	96	11	45
	AVE.				45
0	30	29	97	10	39
2	60	30	98	12	38
	90	30	99	13	38
	120	30	99	11	39
	AVE.				38.5
	30	35	99	13	36
4	60	36	99	12	35
	90	35	100	10	37
	120	33	100	13	35
	AVE.				35.75
	30	38	99	10	32
6	60	40	99	13	33
	90	46	99	12	33
	120	41	99	10	33
	AVE.				32.75
O- 1 /N/I	TIME and	EIO.	0.4.0	D D	CTOO
O ₂ L/M	TIME sec	FIO ₂	SAO ₂	RR	ETCO ₂
U ₂ L/IVI	30	21	97	14	43
0 0					
	30	21	97	14	43
	30 60	21 21	97 97	14 11	43 41
	30 60 90	21 21 21	97 97 97	14 11 12	43 41 45
	30 60 90 120	21 21 21	97 97 97	14 11 12	43 41 45 44
	30 60 90 120 AVE	21 21 21 21	97 97 97 96	14 11 12 14	43 41 45 44 43.25
0	30 60 90 120 AVE 30 60	21 21 21 21 21 22 21	97 97 97 96 97 98	14 11 12 14 12 13	43 41 45 44 43.25 45 46
0	30 60 90 120 AVE 30	21 21 21 21 21	97 97 97 96	14 11 12 14	43 41 45 44 43.25 45
0	30 60 90 120 AVE 30 60	21 21 21 21 21 22 21 21	97 97 97 96 97 98 98	14 11 12 14 12 13 13	43 41 45 44 43.25 45 46 47
0	30 60 90 120 AVE 30 60 90 120 AVE	21 21 21 21 21 22 21 21 22	97 97 97 96 97 98 98 98	14 11 12 14 12 13 13 12	43 41 45 44 43.25 45 46 47 46
2	30 60 90 120 AVE 30 60 90 120 AVE 30	21 21 21 21 22 21 21 22 24	97 97 97 96 97 98 98 98	14 11 12 14 12 13 13 12	43 41 45 44 43.25 45 46 47 46 46
0	30 60 90 120 AVE 30 60 90 120 AVE	21 21 21 21 22 21 21 22 24 22	97 97 97 96 97 98 98 98	14 11 12 14 12 13 13 12 9	43 41 45 44 43.25 45 46 47 46
2	30 60 90 120 AVE 30 60 90 120 AVE 30 60 90	21 21 21 21 22 21 21 22 24	97 97 97 96 97 98 98 98 98	14 11 12 14 12 13 13 12	43 41 45 44 43.25 45 46 47 46 47
2	30 60 90 120 AVE 30 60 90 120 AVE 30 60 90	21 21 21 21 22 21 21 22 24 22 23	97 97 97 96 97 98 98 98 98 99	14 11 12 14 12 13 13 12 9 11	43 41 45 44 43.25 45 46 47 46 47 47 47 47
2	30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE	21 21 21 21 22 21 21 22 24 22 23 23	97 97 97 96 97 98 98 98 98 99	14 11 12 14 12 13 13 12 9 11 10	43 41 45 44 43.25 45 46 47 46 47 47 47 47 47 48 47.25
2	30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE 30	21 21 21 21 22 21 21 22 24 22 23 23	97 97 97 96 97 98 98 98 98 99 99	14 11 12 14 12 13 13 13 12 9 11 10 10	43 41 45 44 43.25 45 46 47 46 46 47 47 47 47 47 47 47 47
2	30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE 30	21 21 21 21 21 22 21 21 22 24 22 23 23 24 24	97 97 97 96 97 98 98 98 98 99 99	14 11 12 14 12 13 13 12 9 11 10 10	43 41 45 44 43.25 45 46 47 46 47 47 47 47 48 47.25 47
2	30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE 30 60	21 21 21 21 22 21 21 22 24 22 23 23 24 24 24 25	97 97 97 96 97 98 98 98 98 99 99 99	14 11 12 14 12 13 13 13 12 9 11 10 10	43 41 45 44 43.25 45 46 47 46 47 47 47 47 48 47.25 47 46 46
2	30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE 30	21 21 21 21 21 22 21 21 22 24 22 23 23 24 24	97 97 97 96 97 98 98 98 98 99 99	14 11 12 14 12 13 13 12 9 11 10 10	43 41 45 44 43.25 45 46 47 46 47 47 47 47 47 48 47.25 47

DEVICE: CAPNOXYGEN mask

O ₂ L/M	TIME sec	FIO ₂	SaO ₂	RR	ETCO ₂
	30	21	97	12	45
0	60	21	96	13	44
	90	21	96	16	46
	120	21	96	11	45
	AVE.				45
	30	30	97	12	39
2	60	31	98	10	38
	90	30	99	13	38
	120	30	99	11	39
	AVE.				38.5
	30	35	99	13	36
4	60	36	99	12	35
	90	35	99	10	37
	120	34	99	13	35
	AVE.				35.75
	30	38	100	10	32
6	60	40	100	12	33
	90	46	99	14	33
	120	41	100	13	33
	AVE.				32.75
Ī					020
O ₂ L/M	TIME sec	FIO ₂	SAO ₂	RR	ETCO ₂
O ₂ L/M		FIO ₂	SAO ₂	RR 14	
O ₂ L/M	TIME sec				ETCO ₂
	TIME sec	21	97	14	ETCO ₂ 43
	TIME sec 30 60	21 21	97 98	14 11	ETCO ₂ 43 41
	TIME sec 30 60 90	21 21 21	97 98 99	14 11 12	ETCO ₂ 43 41 45
	TIME sec 30 60 90 120	21 21 21	97 98 99	14 11 12	ETCO ₂ 43 41 45 44
	TIME sec 30 60 90 120 AVE	21 21 21 21	97 98 99 98	14 11 12 14	ETCO ₂ 43 41 45 44 43.25
0	TIME sec 30 60 90 120 AVE 30	21 21 21 21 21	97 98 99 98 97	14 11 12 14	ETCO ₂ 43 41 45 44 43.25 45
0	TIME sec 30 60 90 120 AVE 30 60	21 21 21 21 21 22 21	97 98 99 98 97 98	14 11 12 14 12 13	ETCO ₂ 43 41 45 44 43.25 45 46
0	TIME sec 30 60 90 120 AVE 30 60 90	21 21 21 21 21 22 21 21	97 98 99 98 97 97 98	14 11 12 14 12 13 13	ETCO ₂ 43 41 45 44 43.25 45 46 47
0	TIME sec 30 60 90 120 AVE 30 60 90 120	21 21 21 21 21 22 21 21	97 98 99 98 97 97 98	14 11 12 14 12 13 13	ETCO ₂ 43 41 45 44 43.25 45 46 47
0	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE	21 21 21 21 21 22 21 21 22	97 98 99 98 97 98 98 98	14 11 12 14 12 13 13 12	ETCO ₂ 43 41 45 44 43.25 45 46 47 46
2	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE	21 21 21 21 22 21 21 22 24	97 98 99 98 97 98 98 98	14 11 12 14 12 13 13 12	ETCO ₂ 43 41 45 44 43.25 45 46 47 46 47
2	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE	21 21 21 21 22 21 21 22 24 22	97 98 99 98 97 98 98 98 98	14 11 12 14 12 13 13 12 10 12	ETCO ₂ 43 41 45 44 43.25 45 46 47 46 47 47 47 48
2	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE	21 21 21 21 22 21 21 22 24 22 23	97 98 99 98 97 98 98 98 98 98	14 11 12 14 12 13 13 12 10 10	ETCO ₂ 43 41 45 44 43.25 45 46 47 46 47 47
2	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE	21 21 21 21 22 21 21 22 24 22 23	97 98 99 98 97 98 98 98 98 98	14 11 12 14 12 13 13 12 10 10	ETCO ₂ 43 41 45 44 43.25 45 46 47 46 47 47 47 48
2	TIME sec 30 60 90 120 AVE 30 60 90 120 AVE 30 60 90 120 AVE 30 AVE 30 AVE 30 AVE	21 21 21 21 22 21 21 22 24 22 23 23	97 98 99 98 97 98 98 98 98 99 99	14 11 12 14 12 13 13 12 10 12 10 12	ETCO ₂ 43 41 45 44 43.25 45 46 47 46 47 47 47 48 47.25
2	TIME sec 30 60 90 120 AVE	21 21 21 21 22 21 21 22 24 22 23 23	97 98 99 98 97 98 98 98 98 98 99 99	14 11 12 14 12 13 13 13 12 10 12 10 12	ETCO ₂ 43 41 45 44 43.25 45 46 47 46 47 47 47 47 47 48 47.25
2	TIME sec 30 60 90 120 AVE	21 21 21 21 22 21 21 22 24 22 23 23 25 24	97 98 99 98 97 98 98 98 98 99 99 99	14 11 12 14 12 13 13 12 10 12 10 12 11 12	ETCO ₂ 43 41 45 44 43.25 45 46 47 46 47 47 47 48 47.25 47